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ABSTRACT
Campion, Christina Marie. PhD. The University of Memphis. December, 2016. The
Role of the EGF Receptor and Its Ligands in Differentiation and 2,3,7,8Tetrachlorodibenzo-p-dioxin (TCDD) Toxicity. Judith Cole, PhD.
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a highly lipophilic polyaromatic
hydrocarbon and a persistent environmental contaminant. In the human epidermis, TCDD
causes enhanced proliferation and altered, accelerated differentiation. However,
epidermal differentiation, mediated by calcium (Ca), opposes and attenuates proliferative
signaling, driven by the epidermal growth factor receptor (EGFR). Using a monolayer
cell culture model, confluent NHEKs were treated with high Ca (1.8 mM) or TCDD (10
nM). EGFR down-regulation, signaling, and proliferation were then examined to assess
the proliferative capacity of differentiating skin versus pathophysiological, TCDDmediated differentiation. We found that while Ca and TCDD caused marked (~50% and
~30%) loss of [125I]-EGF binding, the effects of this down-regulation differed. ERK
activity decreased 45% in Ca-treated cells and increased 300% in TCDD-treated cells.
Utilizing ligand-specific ELISAs to interrogate cell-secreted EGFR ligands which might
drive ERK activity, we found that Ca increased transforming growth factor-alpha (TGFα) secretion, while TCDD increased TGF-α and EREG secretion relative to basal cells.
Amphiregulin (AREG) increased with time in all treatments. Inhibiting ligand secretion
with the MMP inhibitor, batimastat, or action with ligand-specific neutralizing antibodies
in TCDD-treated cells reduced the increased ERK activity to basal levels but could not
rescue ERK activity in Ca-treated cells. Similarly, in TCDD-treated NHEKs,
neutralizing AREG or EREG reversed EGFR down-regulation, and removal of TGF-α
further reduced biotin-EGF binding. In Ca-treated cells, neutralizing EGFR ligands had
no effect on EGFR down-regulation. We then investigated how these treatments
v

influenced proliferative capacity of cell populations through dsDNA quantitation and
EdU labelling. We found that while Ca-treatment led to ~15% fewer cells than basal they
still retained an equal (~5%) amount of EGFR-dependent proliferating cells. Conversely,
TCDD-treatment led to equal cell numbers relative to basal cells, both of which were
reduced following ligand neutralization. However, TCDD-treatment led to a significant
increase in the population of proliferating cells (~8%) relative to basal. Taken together,
our data suggests that in Ca-treated cells, EGFR down-regulation is ligand-independent
and correlated with a loss of proliferative signaling capacity while TCDD-treated cells
down-regulate the EGFR in a ligand-dependent manner, and that TGF-α retains a
population of surface-associated receptors which may drive increased proliferation.
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PREFACE
This dissertation is presented in four chapters including two manuscripts. Chapter
One introduces the current research and frames the experimental question and approach.
Chapter Four ties together results and conclusions from Chapters Two and Three. The
second chapter, entitled “Calcium causes ligand-independent EGFR down-regulation,”
contains the manuscript which is in preparation for submission to the Journal of Cell
Science. Chapter Three entitled “Role of EGF Receptor ligands in TCDD-induced EGFR
down-regulation and cellular proliferation” is published in Chemico-Biological
Interactions volume 253, 23 April 2016. Both manuscripts are written in the format
which aligns with the guidelines set forth by their respective journals. Chapters One,
Four, and the Appendix are referenced in accordance to the guidelines of the journal
Endocrinology.
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CHAPTER ONE
Introduction
Rationale for this Study
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) causes seemingly contradictory
phenotypes of epidermal hyperproliferation and accelerated, though altered, keratinocyte
differentiation (1-5). Previous findings from our lab show that this occurs through an
epidermal growth factor receptor (EGFR)-dependent mechanism which can be attenuated
by the use of an EGFR-inhibitor or an EGFR-specific neutralizing antibody (6). The
literature is divided as to how this phenomenon occurs; several studies suggested that
TCDD stimulates the synthesis and release of EGFR ligands (7-9) while others suggested
that the EGFR is instead activated in a ligand-independent way, such as through
transactivation by phosphatidylinositol-3 kinase (PI3K)- activated phospholipase Cγ
(PLCγ) (10) or through the non-receptor tyrosine kinases (RTK) such as c-src (11, 12).
However, work from several laboratories show that TCDD and calcium (Ca), the
physiological modulator of keratinocyte differentiation, cause EGFR down-regulation
from the cell surface (13-15). EGFR down-regulation, which would attenuate signaling
seemingly contradicts the requirement for epidermal growth factor (EGF)-like ligands
and EGFR activation in TCDD-induced proliferation (14). However, data supporting a
hyperproliferative role of TCDD in keratinocytes has been equivocal, dependent upon
endpoint, treatment protocol, and which cell lines have been used (13, 14, 16).
In this study, we sought to clarify the role of the EGFR and its ligands in mediating the
TCDD-induced proliferation of normal human epidermal keratinocytes (NHEKs) by
addressing the following questions:
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1. What causes the down-regulation of EGFRs observed in Ca differentiated
or TCDD-treated NHEKs?
2. Is the loss of EGFRs associated with a reduction in (or the loss of) EGFR
signaling capacity?
3. What role do individual EGFR ligands play in EGFR down-regulation and
proliferation in Ca- or TCDD-treated cells?
While the literature suggests that crosstalk exists between the aryl hydrocarbon receptor
(AhR) which binds TCDD, other cellular signaling pathways, and the EGFR (12, 17, 18),
our work shows that TCDD enhances the secretion of transforming growth factor-α
(TGF-α) and epiregulin (EREG) while maintaining an environment of high amphiregulin
(AREG). We further found that neutralization of all three ligands is required to reduce
cell number but that neutralization of singular EGFR ligands have unique effects on loss
of surface-associated EGFR and keratinocyte proliferation.
Literature Review
Human exposure to 2,3,7,8-tetrachloro-p-dioxin
TCDD is a ubiquitous environmental contaminant that is not produced
intentionally but persists in the environment due to its lipophilicity and production as a
byproduct in industrial and natural combustion processes in the presence of chlorinated
waste products (19). TCDD is also a product of pulp bleaching in paper production and is
thus found as a contaminant in paper products including, alarmingly, some feminine
hygiene products and diapers at very low levels (20). TCDD is also created during the
production of some herbicides (19). Agent Orange is the most prominent example, but it
has also been produced in other milder pesticides (19)—though many of these have been
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discontinued since by the Environmental Protection Agency (EPA). Due to heavy
regulation of TCDD-producing industries, exposure to high levels of TCDD is
uncommon (19) though lower level exposure is not.
TCDD is a highly toxic and lipophilic chemical which tends to concentrate and
persist in the food chain, particularly in fish. It follows that the major source of exposure
to TCDD and related compounds is dietary (Table 1). The average person carries a
TCDD load of 32 parts per trillion in his or her fat in a steady state (21). Regardless,
these levels, even in the most extreme situations are well below the United States
Department of Agriculture’s reference dose (20, 21). Nevertheless, its persistence in the
body can prolong the effect of even a low dose of TCDD. In a study of Agent Orangeexposed Vietnam War veterans, TCDD was found to have a half-life of 7.1 years (95%
c.i. of 5.2 – 8.6 years) in the human body--much longer than in most laboratory animals
(22). However, TCDD half-life can be much shorter (1-3 years) in patients exposed to
very high levels (>100,000 pg/g lipid weight) (23) and over 10 years for patients exposed
at low levels (<50 pg/g lipid weight) (22). This phenomenon was observed following the
poisoning of Viktor Yushchenko, but also observed in highly exposed individuals from
European occupational or accidental exposures (23). Researchers hypothesized that this
was due to a higher concentration of activating metabolizing enzymes in the skin or liver
(23). By a similar rationale, a meta-analysis found that half-life could also be
dramatically reduced in patients who were regular smokers, owing to the smoke’s
induction of cytochrome P450 1A1 (CYP1A1) (24). TCDD has also been shown to have
a shorter half-life in individuals with a lower percentage of body fat, owing to a smaller
reservoir for TCDD storage (25) , as well as for patients who are under 18 at time of
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exposure due to rapid growth and turnover of lipid stores, breastfeeding women, and
individuals on drugs used to mobilize fats (23, 24). However, weight loss post-exposure
did not affect serum levels of TCDD (24).
The preceding information reveals how difficult it is to quantify TCDD’s relative
toxicity in the human body. The National Institute for Occupational Safety and Health
(NIOSH) has not determined a relative exposure limit or an immediately danger to life
and health limit, nor has Occupational Safety and Health Administration assigned a
permissible exposure limit (19). However NIOSH notes TCDD to be an occupational
carcinogen (19). Even in animals, the LD50 varies between 500 ng/kg body weight in
guinea pigs to over 1.1 mg/kg body weight in Siberian hamsters (26). Within strains or
even sexes of rats, fold-level differences can exist (26, 27) and studies in NHEKs in vitro

Table 1. Average dietary TCDD exposures (21)
Food
Ocean fish
Freshwater fish
Meat
Cheese
Milk

[TCDD] (pg/g)

Average daily TCDD intake
pg/person/day
8.6
-6.6
0.31
0.20

500
70
35
16
1.8

show an order of magnitude in individual variation of EC50 (0.45 nM – 1.41 nM) of
TCDD in four donor cell lines (28). LD50 has not been determined in humans due to the
paucity of lethal dose exposures to TCDD, though it appears to be on the higher end of
the interspecies range presented above (23, 29). Still, regulatory bodies maintain that
even low level exposures can be harmful. While the effect of chronic, low level exposure
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to TCDD is difficult to parse, several large scale accidental or intentional exposures have
brought TCDD into the public eye and helped elucidate the effects of TCDD on human
health in vivo.
Large-scale exposures since World War II
Food contamination: Dioxins and other polyaromatic hydrocarbons (PAHs)
bioaccumulate in fatty tissue in animals, but there have been several incidences over the
past few decades involving excessive contamination from dioxins or other PAHs such as
polychlorinated biphenyls (PCBs) or polychlorinated dibenzo-furans (PCDFs). The most
famous case occurred in 1968 in the Japanese Kyūshū province. Rice bran oil was
contaminated by PCBs, affecting 14,000 people, and over 400,000 birds who died of
respiratory distress. In humans, a disease called Yusho disease was identified, marked by
skin and eye lesions, irregular menstruation in women, weakened immune responses, and
cognitive defects in children. In 1979, Taiwanese rice bran oil was similarly
contaminated, causing many of the same symptoms and referred to as YuCheng illness
(30). These, as with most environmental contaminations, were of a mixture of PCBs and
PCDFs compared to laboratory based studies which tend to use TCDD (30). However,
victims in the Yusho and Yucheng group have been closely monitored for the past four
decades for outcomes on reproductive health, cancer incidence, skin manifestations of
PCDF intoxication, and metabolic syndromes (31). One difference between the two
exposures is that a coplanar PCB in the Yusho incident appears to be linked with thymic
atrophy and decreased androgen metabolism, contributing to reproductive effects
observed in exposed women (32). Women were also more strongly affected in the
Yucheng cohort with increased risks of diabetes, chloracne, or hypertension compared to
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a control population (33). As recently as 2008, a dioxin contamination of Irish pork
caused a worldwide recall, though fortunately the European Union recognized this before
it caused a global health crisis. About 10% of the population of Ireland was exposed to
meat thought to have been contaminated through animal feed (34). It is too soon to see if
chronic health problems have arisen from these exposures, but early data indicate TCDD
has not been elevated in breast-milk of first time Irish mothers, though some increase in
PDCFs was observed (35).
Seveso, Italy: On July 10, 1976, a factory in Seveso, Italy, 9 miles north of Milan
exploded. The factory produced 2,4,5-trichlorophenol, an intermediate for
hexochlorophene, an antibiotic used in toothpaste and soaps, and for 2,4,5trichlorophenoxyacetic acid, an herbicide (36). TCDD was created unintentionally as a
byproduct of this reaction and of the 6 tons of chemicals released. 1 kg of TCDD was
distributed over an 18 km2 area, in some areas as high as 100 ppm (36). Within days,
3,300 animals, mostly poultry and rabbits were found dead, and over the next two years
80,000 animals were slaughtered to prevent bioaccumulation within the food chain. Over
5,436 humans lived within an area with soil concentrations > 5 µg/m2 (36). This
represents the largest scale human exposure in a residential population to date and the
cancer and disease incidences of these exposed populations has been extensively
followed in the nearly 40 years since. (37).
Love Canal, New York: From 1942 until 1953, Love Canal, NY was used as a
dumping ground for waste from the Hooker Electrochemical Company, the US military,
and the city of Niagara Falls. Here, Hooker stored 55 gallon drums of industrial waste,
including “caustics, alkalines, fatty acids and chlorinated hydrocarbons from the
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manufacturing of dyes, perfumes, solvents for rubber and synthetic resins (38, 39)." After
1953, the canal was paved and sodded over, and sold to the Niagara Falls City School
District for $1 (U.S.). They built a school and surrounding community on the site (39).
Love Canal represents persistent exposure like Seveso. Twenty years later ground water
testing showed the presence of dioxins at ~53 parts per billion as a result of seepage from
the dump into the sewer. Further research showed an increased incidence of miscarriages
and birth defects in children born in Love Canal (40, 41). Infants born to exposed
mothers were also more likely to be preterm, at a low birth weight, and had a skewed
male:female ratio (41). Children born and raised in Love Canal suffered increased
incidences of epilepsy, cognitive disorders, eye problems, and skin rashes (38). Nearly
1/3 of the population showed high white blood cell counts and chromosomal damage,
considered to indicate increased likelihood of leukemia (42) and after 30 years, one study
found a slightly elevated incidence of bladder and kidney cancer in former Love Canal
residents, though the sample size was too small to draw definitive conclusions. No
increase in all-cause mortality was observed (43, 44).
Times Beach, Missouri: Times Beach, Missouri was a town of around 2000
people located 17 miles south of St. Louis and the site of another mass exposure to
TCDD (45). In 1972, the City of Times Beach paid a subcontractor to pressure wash
2400 feet of dirt roads within the town. This subcontractor who owned a trucking and oil
business, had also held contracts for waste disposal for the Northeastern Pharmaceutical
and Chemical Company, Inc., a company that manufactured hexachlorophene from 2,4,5trichlorophenol (the same chemical manufactured in Seveso). This subcontractor used the
same trucks to carry dioxin contaminated wastes as he did to pressure wash the roads and
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over the next four years, he sprayed an estimated 160,000 gallons of toxic waste on the
roads (45). In 1983, dioxin concentrations on the roads were still measured at 0.3 ppm
(46). Interestingly, the public health ramifications of Times Beach were minimal at best
as no cases of chloracne, the hallmark condition of dioxin exposure were observed (47).
In fact, a 1991 EPA report questioned whether the Times Beach evacuation had really
been necessary (48) and in 1997, Times Beach was removed from the list of superfund
sites needing cleanup (47). Further, soil samples as of November 2012 indicate that
Route 66 State Park in Times Beach now poses no threat to park visitors or workers (47,
49).
Viktor Yuschenko’s poisoning: The most public instance of dioxin in the news
was the 2004 poisoning of Ukrainian presidential candidate Viktor Yushchenko.
Yuschenko was admitted to hospital in early September 2004 with acute pancreatitis, and
over the coming months developed a disfiguring skin condition, identified by doctors as
chloracne (23). In December 2004, serum samples from Yushchenko confirmed a level of
108,000 pg/g lipid weight laboratory-grade TCDD-- more than 50,000 times that of the
general population (23). Over the next three years, a team of doctors monitored
Yushchenko’s blood, urine, feces, skin, sweat, and material extracted from skin lesions
for levels of TCDD and its metabolites, as 2,3,7-trichloro-8-hydroxydibenzo-p-dioxin
(OH-TriCDD) and 1,3,7,8-tetrachloro-2-hydroxydibenzo-p-dioxin (OH-TCDD) wherein
they were able to make several determinations about TCDD metabolism and secretion in
humans (23). Doctors found that most TCDD was excreted fecally, a similar finding to
observations in rodents (27). They also found that most excreted TCDD was
unmetabolized, particularly in the skin and serum, though fecal samples contained the
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highest concentration of metabolites (23). Further, Sorg et al. discovered a high
concentration of TCDD in samples removed from TCDD-induced skin lesions,
suggesting a new mechanism for TCDD elimination (23). In Yushchenko, researchers
found TCDD to have a half-life of 15.4 months, much shorter than expected even with
his high initial serum levels. Some of this accelerated metabolism was attributed to
frequent surgery and biopsying as well as to pharmacological interventions which
enhanced cytochrome P450 1A2 (CYP1A2) expression and dioxin metabolism, and
mobilized lipid turnover, depleting the reservoir for dioxin, such as Olestra and Orlistat
(23).
Molecular and genetic actions of TCDD
Epidermal hyperproliferative disorders are frequently caused by genetic and
idiopathic factors, and chemicals have also been shown to replicate this disease
phenotype. 2,3,7,8-tetrachlorodibenzo-p-dioxin (Figure 1) is the most potent congener in
a class of polychlorinated dibenzodioxins (19) and binds to a receptor known as the AhR
(50).

Figure 1. Structure of 2,3,7,8-Tetrachlorodibenzo-p-dioxin (19)
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The AhR is an ligand-activated transcription factor and serves as a basic helixloop-helix transcription factor containing a Per-Arnt-Sim domain (bHLH/PAS) which
binds polyaromatic and halogenated aromatic hydrocarbons (51). In its unliganded form,
the AhR is cytosolically bound to several proteins including heat shock protein 90
(Hsp90) (50). Upon ligand binding (Figure 2), the nuclear localization signal on the AhR
is exposed, allowing the AhR to migrate to the nucleus where it partners with ARNT, the
aryl hydrocarbon receptor nuclear translocator (52). The AhR-ARNT heterodimer binds
DNA at 5-7mer sites identified as xenobiotic response elements (XREs) with a consensus
sequence of TnGCGTG (with n indicating any base) (53). Although this is the
most clearly understood mechanism of AhR activation, very few genes have been
confirmed to be controlled directly through an XRE. A computerized search of the human
genome discovered 72,318 putative XREs and found further that XREs were more
heavily concentrated in coding regions of DNA compared to non-coding regions, and
were most concentrated within 1.5 kb of the transcription start site (TSS) (54). Canonical
genes induced following AhR activation include cytochrome P450 1A1 and 1B1
(CYP1A1 and CYP1B1) (52, 54) both of which been confirmed as XRE-dependent in
mouse, and CYP1A1 has been confirmed in rat (54-56). CYP1A1 and CYP1B1 are
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Figure 2. Canonical and non-canonical mechanisms of AhR-mediated
activation A. TCDD-dependent activation of AhR through AhR/ARNT binding at
an XRE sequence leads to upregulation of target genes (53, 63) B. TCDD-dependent
estrogenic activity through AhR/ARNT/Estrogen Receptor α (ERα) at an estrogen
response element (ERE) or estradiol (E2) dependent activation via E2 classical
pathway lead to an upregulation of c-myc (64). C. TCDD-dependent anti-estrogenic
activity through AhR/ARNT binding to inhibitory XRE (iXRE) sequences, blocking
ERα homodimer binding to ERE sites leading to a downregulation of c-myc (64). D.
Xenobiotic metabolism may create estrogenic metabolites, antiestrogenic
metabolites, or ROS. Sod1 removes ROS from the cell. (18).
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members of the cytochrome P450 protein family of monooxygenases that are involved in
xenobiotic and drug metabolism, a logical target for the AhR (52). CYP1B1 in particular
hydrolyzes PAHs and 17β-estradiol (57, 58). Genes involved in metabolism, lipid
synthesis, and response to reactive oxygen species (ROS) are also directly regulated by
the AhR including: aldehyde dehydrogenase 3 family member A1 (Aldh3a1), NAD(P)H
dehydrogenase, quinone 1 (Nqo1), glutathione S-tranferase alpha 2 (GSTA2), UDP
glucuronosyltransferase 1-6 precursor (Ugt1A6) were verified as XRE-mediated in rats
(54, 59). Superoxide dismutase 1 (Sod1) converts superoxide radicals to molecular
oxygen and hydrogen peroxide (H2O2) which can then be broken down by catalase.
Catalase is critical in the cellular ROS response and has been shown to be XRE-mediated
in humans and in rats, presumably to aid in neutralization of ROS generated as xenobiotic
metabolites (60, 61). Nevertheless, XRE-mediated genes directly related to keratinocyte
differentiation are still largely undescribed. In mice, the EGF receptor ligand EREG is
regulated by an XRE, though this finding has not been replicated in humans (9). Finally,
work from our lab has shown Filaggrin (Flg), a marker of keratinocyte differentiation, to
be likewise regulated by an XRE 1400 bp upstream of its TSS (18).
Increasingly, there has been discussion of non-canonical mechanisms of action of
the AhR, particularly those pertaining to its endocrine disrupting actions (Figure 2B-C).
TCDD and many planar hydrocarbons in its class can have anti- or pro-estrogenic effects
which may be tissue- specific (62). In porcine ovarian cells, TCDD was shown to affect
estrogenic signaling and oocyte maturation at the level of steroidogenesis through
inhibition of P450 cholesterol side chain cleavage enzyme (P450SCC) and aromatase
(63), fundamental steps in estrogen synthesis. This finding was echoed in rainbow trout
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where TCDD inhibited P450SCC and steroidogenic acute regulatory protein (stAR) (64).
Aluru et al. also showed that TCDD-exposed trout produced less cortisol following an
adrenocorticotrophic hormone (ACTH) challenge, suggesting TCDD exposure may
decrease glucocorticoid production and diminish stress responses (64). The AhR can
directly bind the ERα, and the AhR/ARNT/ERα can either signal through estrogenregulated genes in the absence of E2 or bind inhibitory iXREs located near EREs,
conformationally blocking the binding of ligand bound ERα (65, 66).
The AhR can function as a mediator of inflammation in several ways: directly,
through XRE-mediated induction of inflammatory cytokines involved in Th17 cell
differentiation, particularly (interleukin) IL-22, IL-23, and IL-1A, as well as the retinoidrelated orphan receptor (RORα) (67, 68). This may also be due to the ability of AhR to
bind nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) (69, 70).
This likely evolved as lipopolysaccharide (LPS) binds the AhR, however, pathologically,
it leads to a hyperinflammatory feedforward loop that explains dioxin’s role in persistent
inflammation in vivo (70, 71). AhR binding to NF-kB also serves as a mechanism of cell
cycle inhibition wherein AhR sequesters NF-kB, attenuating its role in DNA-synthesis
(72). AhR can also inhibit cell cycle progression by sequestering pRb which
preferentially binds to the liganded Ahr (66, 69). Finally, AhR can alter cellular sex
steroid signaling by functioning as a ligand-dependent scaffolding molecule within cullin
4b E3 ubiquitin ligase complex which targets these hormones for degradation (73).
Overall, the AhR has a variety and wide ranging subset of cellular and tissue
responses from hormonal, to inflammatory, to proliferative. While it is likely that some
effects of TCDD on epidermal differentiation are mediated through canonical, XRE-
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mediated routes, it is possible that cofactor competition, or non-canonical mechanisms
are mediate TCDD-accelerated epidermal differentiation.
Health risks of TCDD exposure
As discussed above, population-wide acute or chronic exposures to TCDD have
given researchers insight into target tissues for PAHs. TCDD intoxication produces or
contributes to a variety of diseases in four major categories: 1) immunotoxic and
inflammatory, 2) oncogenic, 3) reproductive and developmental, and 4) skin (74).
Immunological effects: The immune system is complicated and intrinsically tied
to tissue homeostasis throughout the body, however there is evidence that the immune
system is a site of toxicity for TCDD. Prolonged dioxin exposure causes thymic atrophy
in rats (27), a response also recognized in YuCheng victims (32). It is suggested that an
AhR-mediated loss of NF-kB signaling which is required for normal medullary thymic
development is involved in this thymic atrophy (70, 75). Lacking a competent thymus,
the patient has difficulty with T-Cell maturation, which TCDD further compounds.
Individuals exposed to PAHs in utero show poor notch1-induced T cell differentiation,
predisposing them to T-acute lymphocytic leukemia (T-ALL) (76). Further, TCDD
promotes Th17 maturation in a seemingly direct, XRE-mediated manner (68) which is
linked to increased inflammation and autoimmunity. Nude mice, which congenitally lack
T cells, are less sensitive than their immunocompetent littermates (77). These changes in
immune cell function cause an increased susceptibility to infection and a hypersensitivity
to LPS (78). While it was originally thought that this enhanced susceptibility was specific
to gram negative bacteria, it has also been shown to increase rates of infection, morbidity,
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and mortality from gram positive bacteria (79), viruses (80, 81), parasites (82, 83), and
even establishment of transplanted neoplasms (84).
Oncogenic effects: TCDD is classified as a known human carcinogen, (19).
While victims of the 1976 Seveso disaster showed increased incidences of metabolic
disorders and blood cancers (85), a meta-analysis of TCDD-exposed populations show an
increased risk of cancer in general as opposed to a specific type (86, 86). However when
these findings were applied to Agent Orange-exposed military veterans or smaller
occupational groups, the all-cancer risk was not supported (87). In animal models, mice,
rats, and hamsters exposed to TCDD reliably developed tumors in multiple organ systems
(88). In fact, TCDD-induced tumor development in these rodent models increased in a
dose-dependent manner (88).
Others suggest that TCDD functions not as a direct mutagen, but as a tumor
promoter, leading to more tumors following tumor initiation studies (89, 90). Interspecies
variability in sensitivity and LD50 as well the ethical inability to perform these same
experiments in humans outside of cell culture leave these opposing hypotheses
unanswered (26, 91). In female rats, the LD50 is twice that in males (45 µg/kg to 22
µg/kg, respectively) (88). This makes prediction of toxicity dose based upon exposure
level imprecise. The toxic equivalency factor which quantitates the potency of a ligand is
established based upon toxicity in male rats and fails to take into account interspecies or
interstrain pharmacogenomic differences in rodents, but also population level variance in
sensitivity for humans exposed to admixtures of PAHs in large or, even small, scales
(92).
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Where the evidence for TCDD-mediated oncogenesis is somewhat stronger is in
the offspring of acutely TCDD-exposed parents. In rats exposed in utero exposure are
predisposed offspring to mammary cancer by increasing the numbers of terminal end
buds. Additionally, mice exposed to TCDD in utero are predispose to T-ALL as a result
of desensitizing them to notch1-signaling which drives T cell development (76), and
children of Agent Orange exposed veterans have increased incidences of
rhabdomyosarcoma (93).
Reproductive and developmental effects: One of the most common fears
regarding endocrine disrupting chemicals is that they will mimic estrogen in males,
feminizing them. However endocrine disrupting chemicals can function in a variety of
ways including : 1) inhibition of aromatase which converts testosterone to E2; 2)
antagonism or agonism of the ERα which can be anti- or pro-estrogenic; 3) agonism or
antagonism of the androgen receptor; 4) agonism of the AhR which can inhibit or activate
ERα; 5) interaction with steroid binding proteins; and 6) altering hormone metabolism
(94) . Effects have been seen on male reproductive health and hormones: PCB exposure
in the YuCheng incident has led to decreased serum androgen and gonadal testosterone
synthesis in male patients (32). TCDD exposure in rats leads to decreased epididymal
sperm count through an apoptotic rather than anti-spermiogenesis mechanism (95, 96).
Other works in rats and hamsters confirmed lowered sperm count and demonstrated
decreased sex organ size and reduced semen quality, in the presence of normal levels of
androgens. However, it is in the hypothalamic-pituitary-gonadal (HPG) axis of women
where TCDD has its most marked effects.
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TCDD can lower fertility in both males and females (97, 98). However, in
women, TCDD also increases the risk involved in a pregnancy. Pregnant women suffer
from higher incidences of miscarriage following TCDD exposure (41) and enhanced
placental inflammation which, if insufficient to cause a miscarriage, can lead to preterm
birth or incidences of endometriosis (99). TCDD can be detected in the breast milk of
lactating mothers who have been exposed to high levels of TCDD (35). Further, twenty
years after the Seveso incident, researchers observed a strongly elevated incidence of
breast cancer in 900 women exposed to high levels of TCDD (100). However at thirty
years, this was no longer significantly different than the population at large (37).
The risks of TCDD exposure in utero and in newborns are greater still. Following the
Seveso incident, 30 pregnant women in Zone A nearest the site had induced abortions,
and 4 women who had been pregnant during the incident spontaneously miscarried (100).
Of these, no gross morphological, or obviously fetotoxic effects were observed, though
the spontaneous abortions showed structural abnormalities (100). The small number of
embryos, often incomplete structurally, is not sufficient to rule out a damaging effect of
in utero exposure (100). More, observations from Love Canal support this hypothesis.
What initially drew attention to the contamination in Love Canal was a higher rate of
miscarriage, as well as a higher rate of birth defects (101), matching a finding previously
observed in mice where in utero exposure caused cleft palate (102, 102) . Learning and
cognitive disabilities were seen in children raised in Love Canal or exposed in utero to
contaminated rice bran oil (31, 41). Children born in Love Canal were more likely to be
low birth weight or premature (41). But these observations were all made in very small
populations, making definitive conclusions difficult.
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Dermatologic effects: The hallmark symptom of TCDD exposure in humans is
chloracne (74). Chloracne is characterized by hyperproliferation and altered
differentiation of the interfollicular epithelium as well involution and hyperkeratinization
of the pilosebaceous unit which is comprised of the hair follicle and sebaceous gland
(74). Comedones on the interfollicular epidermis contain a higher concentration of TCDD
than unaffected skin, directly linking chloracne to the disease (23). Interestingly,
chloracnegenesis seems inversely proportional to cancer, perhaps due to increased
secretion of TCDD through dermal lesions leading to a shorter window of exposure. In a
report studied twenty years after the Seveso incident, no individuals who developed
chloracne shortly after the explosion subsequently developed cancers (85).
As chloracne is one of the most common morbidities of humans following TCDD
exposure, the skin becomes an ideal model in which to study TCDD biology. TCDD
causes a variety of effects on the skin, upregulating genes involved in epidermal
differentiation, including 24/60 of the genes on the Epidermal Differentiation Complex, a
region on chromosome 1q21 (18). In mice, TCDD exposure caused epidermal barrier to
form one day earlier in utero in what has been shown to be a Flg-dependent manner (5).
TCDD has been shown to upregulate Flg mRNA in an XRE-dependent manner (1) and
this upregulation is blocked by stimulation of the EGFR (6). TCDD has been shown to
accelerate barrier formation through the increased synthesis of barrier lipids (103). In
addition, TCDD upregulates EGF-like ligands which could drive hyperproliferation (7, 9,
104).

18

The Structure of Human Skin
Skin is the body’s largest organ (Figure 3A), and provides the first line of defense
against external threats. It also plays an important regulatory role against desiccation
(105). The epidermis, comprised of highly stratified squamous epithelial cells, provides a
physical and watertight barrier (105). It is interspersed with tissue- specific macrophages,
called Langerhans cells, sensory receptors called Merkel disks, and melanin-producing
cells called melanocytes (106) which collectively provide a physical, biochemical, and
adaptive barrier (107).
The epidermis also plays an important role in vitamin D synthesis following sun
exposure (108). Sunlight causes the conversion of 7-dehydroxycholesterol (7-DHC) in
the membrane of keratinocytes and dermal fibroblasts to to cholecalciferol (vitamin D3).
Cholecalciferol is hydroxylated in the liver to make 25-hydroxyvitamin D3 (25(OH)D3).
25(OH)D3 is further hydroxylated in the kidney by 1-alpha-hydroxylase to form 1,25dihydroxy-vitamin D (1,25-(OH)2D3). This end product, calcitriol, regulates Ca intake
enterically and the release of Ca from the mineralized matrix of bone. Melanocytes
embedded in the epidermis counterbalance this vitamin D production by absorbing excess
Ultraviolet B (UVB) and preventing 7-DHC activation (109). Skin color is dependent
upon the inherited density and clustering of granular melanosomes in melanocytes (with
caucasian skin having fewer often in clusters while darker skin has more diffusely
distributed melanosomes (110)), UVB radiation also causes branching of dendritic
shaped melanocytes and the increased trafficking of melanin-containing melanosomes,
to decrease ultraviolet (UV) light-induced damage to DNA. This also causes a induced
darkening of the skin, such as tanning or photoaging (108, 110)
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The same cells that give rise to the epidermis also gives rise to the pilosebaceous
units, comprised of hair follicles and sebaceous glands (106), or in hairless regions,
sebaceous glands which cover all of the body except the soles of the feet and hands (111).
The sebaceous gland secretes sebum, a waxy substance comprised of triglycerides,
squalene, wax esters, and other lipid metabolites (112). Sebum serves to lubricate and
further waterproof the epidermis as well as acidifying the skin to a pH between 4.5 and
6.2 which serves as a barrier against bacteria, viruses, and dermal contaminants (113). In
high temperatures, sebum emulsifies sweat from eccrine sweat glands (also embedded in
the epidermis) to further cool the body (114). Hair follicles and sebaceous glands are
maintained by stem cells located in in the follicular bulge (115). Epidermal hair serves a
thermoregulatory and sensory function.
Below the epidermis lies the dermis: a highly vascularized and innervated layer
comprised of fibroblasts, adipocytes, and macrophages in an extracellular matrix (ECM)
comprised of collagen, elastin, and a loose reticular extrafibrillar matrix consisting of
proteoglycans and glycosaminyoglycans (105, 115). Within the dermis are blood vessels
and capillary beds which provide oxygen to epidermal keratinocytes, and a variety of
sensory neurons for pressure, temperature, and pain (115). Below the dermis lies the
hypodermis, which stores subcutaneous fat that further stabilizes body temperature and
can be broken down to provide energy (115).
The Structures of the Epidermis
Stratum Basale: Within the epidermis, a single layer of cuboidal basal cells sits
in contact with the basement membrane of the dermis via hemi-desmosomal structures
[Figure 3B and see (116)]. This contact provides cells access to the dermal ECM and
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Figure 3. Human skin and accessory structures, the epidermis, and the cornified envelope. A) The human skin is derived from the
mesoderm embryonically and is comprised of multiple layers. The superficial epidermis provides a defensive epidermal barrier and
prevents desiccation. The dermis provides structural support to the epidermis as well as vascularization and innervation for pressure,
temperature and pain. Below the dermis lies the subcutaneous layer which is primarily used for fat storage (115). B) The epidermis is
comprised of keratinocytes and contains melanocytes, and skin-specific macrophages known as Langerhans Cells. As keratinocytes
lose contact with the basal lamina (BL) and move from basal to suprabasal layers. they undergo terminal differentiation as they move
from the stratum basale (SB) through the stratum spinosum (SS) and stratum granulosum (SG) towards the stratum corneum (SC)
where they express layer-specific markers of differentiation (left). C) In the stratum corneum, cells extrude lamellar bodies containing
ceramides, fatty acids and cholesterol outside the cell. The membrane of the mature, anucleate keratinocyte (corneocyte) has also
undergone structural changes including the cross-linking of small proline-rich proteins (SPRR) to membrane proteins such as loricrin
(Lor) and involucrin (Ivl). Corneocytes have also undergone keratinization where keratins 1 & 10 are crosslinked and bundled together
by filaggrin (Flg).
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also provides juxtacrine signals that maintain the basal cells in a proliferative,
undifferentiated state (107). The stratum basale contains pockets of proliferative cells that
asymmetrically divide to maintain the epidermal stem cell population and produce a
population of transit-amplifying daughter cells (TACs) which migrate superficially into
the suprabasal layers (117, 118). TACs are an undifferentiated population of cells
transitioning between multipotent stem cells and differentiated cells (119). These
daughter cells are already expressing markers of the earliest phases of keratinocyte
differentiation, keratin-5 and -14 (K5, K14) and p63 (119).
Stratum Spinosum: Suprabasal keratinocytes become increasingly differentiated
as they move towards the stratum corneum, the uppermost layer of the epidermis (107).
As cells progress towards the epidermal surface through the stratum spinosum and
granulosum to the stratum corneum (Figure 3B), they undergo profound morphological
changes and consist of populations of cells transitioning between multipotent stem cells
and differentiated cells. They begin to express markers of differentiation. In the stratum
spinosum, cells have lost contact with the basal membrane and begin to increasingly rely
upon on transitional desmosomal contact and tight junctions (TJs) with other
keratinocytes for juxtacrine signaling and maintenance of differentiation status (105). TJ
proteins such as claudins 1, 4, and 7, as well as occludins and zona occludens protein 1
(ZO1) are expressed in the stratum spinosum (105). These TJs serve to enhance
epidermal barrier function in the case of disruption of the stratum corneum (120) and
mice defective for occludins or claudins die from excessive water loss shortly after birth.
In addition, aberrant expression of claudin-4 and occludin have been linked to epidermal
diseases such as psoriasis vulgaris, ichthyosis, and lichen planus (121). Cells within the
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stratum spinosum also change their protein expression. These proteins, including k1 and
k10, envoplakin (Evpl), periplakin (Ppl), 14-3-3δ, and members of the S100 family of
Ca2+ binding proteins [S100a7, S100a8, S100a9 and S100a10 (122-125)], are important
in barrier structure and function and serve as markers of keratinocyte differentiation
(Table 2).
Stratum granulosum: As cells progress into the stratum granulosum, cell
morphology progresses towards a more squamous phenotype, exemplified by flat, scalelike cells, and an increased cytoplasm: nucleus ratio. High extracellular Ca (>1 mM)
leads to the formation of keratin-rich cytoskeletons linked and stabilized at desmosomes
through desmoglein 1 (Dsg1), a desmosomal cadherin (126, 127). Dsg1 inhibits EGFR
signaling in the stratum granulosum and firmly commits cells to terminal differentiation
(128). Higher extracellular Ca further raises intracellular Ca mediated by the Ca receptor
(CaR) whose expression is regulated by 1,25-(OH)2D3 (123, 129). The CaR activates
PLC signaling, particularly PLCβ and PLCγ1 which ultimately leads to the upregulation
of several markers of differentiation and cornified envelope (CE) precursors such as
transglutaminase 1 (Tgm1) and Flg (11). Increased intracellular Ca is required for the
redistribution of signaling molecules such as protein kinase C (PKC)-α and calmodulin to
the membrane (130), metalloproteinase and Tgm1 activation (131-133), and is correlated
with the expression of markers of differentiation such as Flg (a protein that bundles
keratins (1, 107, 134)) and two Tgm substrates involucrin (Ivl) and loricrin (Lor) (135).
Stratum Corneum: Within the stratum corneum (Figure 3C), terminally
differentiated cells undergo nuclear degradation as part of a specialized program of cell
death called cornification (136). While cornification leads to nuclear and DNA
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degradation as is typically seen in apoptosis, it is a slower and Ca-dependent process
wherein organelles are lysed but DNA is not fragmented. Further, cells remain
metabolically active, though mitotitically inactive until eliminated by desquamation
(137). Corneocytes (fully differentiated, anucleate cells of the stratum corneum).

Table 2. Epidermal markers of differentiation by layer
Epidermal Layer

Gene markers

Reference

Stratum corneum

Lor, Flg, SPRR, Ivl, Cnfn

(121)

Stratum granulosum

(105, 119)

Stratum spinosum

Ivl, Tgm3, Tgm5, Claudins,
Desmogleins, Desmocollins, Cdsn
K1, K10, Tgm1, Evpl, Ppl

Stratum basale

K5, K14

(105, 118, 138)

Basal lamina

α6β4 Integrin, Lama5

(105, 118, 138)

(105)

Abbreviations: Loricrin (Lor), Filaggrin (Flg), Small proline-rich protine protein
(SPRR), Involucrin (Ivl), Cornifelin (Cnfn), transglutaminase (Tgm), Corneodesmosin
(Cdsn), Keratin (K),Laminin-5 (LAMA5)

undergo changes in membrane lipid composition and Tgm1-mediated cross-linking of
membrane associated proteins, predominantly Lor, Ivl, and keratins to form a structure
known as the CE (107, 137). Interestingly, extracellular Ca drops in the stratum corneum,
an event that precedes the extrusion of lamellar bodies from the cytoplasm and formed in
the stratum granulosum (139). The specialized lipids contained within these lamellar
bodies help to form a watertight matrix in which a multi-layered physiochemical barrier
of mitotically inactive, insoluble cells lie within a matrix of specialized membrane lipids
similar to “bricks and mortar” in a wall (105).
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The stratum corneum is continuously lost through desquamation allowing
keratinocytes from the suprabasal layers to take their place (107). The stratum basale
maintains this population of cells through the continued production of TACs from the
epidermal stem cell population maintained therein, (115, 140). The average turnover of
the normal epidermis occurs in 40-56 days in vivo in humans and 8-10 days in murine
skin (141); However, this turnover time can be shortened with disruption to epidermal
barrier as in the case of wound healing (142, 143).
The signals governing keratinocyte differentiation versus proliferation are tightly
regulated through the interplay of mitogenic cell-basal laminar interactions and factors
such as growth factors and inhibitory micro-environments with increased extracellular
Ca, decreased EGFR signaling, and loss of basal-laminar interactions. Further,
toxicological or pharmacological interventions can modify epidermal homeostasis. As
such, altered proliferation and/or differentiation are implicated in many dermatological
conditions, such as psoriasis (142, 144, 145). Epidermal turnover occurs every 28-45
days in the presence of increased inflammation leading to the development of
characteristic thick, pruritic plaques and lesions (142). Desmosomal connections or
cytoskeletal components are frequently altered or lost in common epidermal diseases
(Table 3).
Ca as a physiological regulator of epidermal differentiation
As discussed above, Ca is an important modulator of epidermal differentiation.
Within the epidermis, Ca is lowest in the stratum basale, increases steadily reaching its
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Table 3. Skin diseases with disrupted barrier show cytoskeletal aberrations
Disease

Cause

Genes altered

Presentation

Reference

Atopic
dermatitis

Genetic or
autoimmune

Flg

Dry skin overall with patches of itchy, red, swollen, cracked skin.
More common in children

(134, 151, 152)

Epidermolysis
bullosa

Genetic

K5, K14

Fluid filled blistering following pressure

(153)

Harlequin
ichthyosis

Genetic

Severe hyperkeratosis and greatly accelerated epidermal
proliferation. Reduced lipid transfer across the membrane leads to
diamond shaped scales and cracked, exposed skin

(154)

Ichthyosis
vulgaris

Genetic

ATP-binding
cassette
transporter 12
(ABCA12)
Flg

Thickened, cracked skin forming “scales” that improve with age

(155-157)

Lamellar
ichthyosis

Genetic

Tgm1

Extensive scaling of the skin with hyperkeratosis

(156, 157)

Pemphigus

Autoimmune

Dsg1, Dsg3

(153)

Psoriasis

Immunemediated
inflammatory

PSORS1-9
CDSN

Epidermal acantholysis forming painful, non-pruritic blisters
beginning in the mouth (pemphigus vulgaris) or the scalp, back,
and arms (pemphigus foliaceus)
Thickened epidermis and loss of stratum granulosum. Plaques
covered with silvery scales with erythrymatous borders
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(142, 158)

peak in the stratum granulosum and then dropping again within the stratum corneum
(146, 147). As cells similarly progress from basal to suprabasal epidermal layers, high
extracellular Ca can cause genomic and non-genomic effects (148) such as increases in
expression of markers of differentiation [e.g. Ivl, Lor, and Tgm1 protein within hours
(149)], and increased cornification at 1-2 days (150). High extracellular Ca has also been
shown to have non-genomic effects on cellular homestasis such as redistribution of
desmoplakin (DP), a desmosomal protein that anchors intermediate filaments in
desmosomes to the membrane (141) and increases in cell-cell adhesions (15), both of
which are important in establishing and maintaining epidermal barrier (115, 159, 160).
Ca is also required for the activation of differentiation-related Tgm1 which crosslinks
proteins in the CE (107) as well as for the activation of several metalloproteinases
essential for migration through the epidermis (131, 133, 161). Ca increases the protein
phosphotyrosine content in keratinocytes, activating the non-RTKs fyn (12) and src (11,
162). Through the use of signaling defective mutants of src and fyn, Xie et al. showed
that these non-RTKs as well as PI3K can phosphorylate PLCγ1 which is required for
keratinocyte differentiation in a PI3K-dependent manner (10, 11).
The cause of this epidermal Ca gradient is not entirely clear however it has been
shown to be integral to the epidermal barrier formation and differentiation processes
(139). Disruption of the epidermal barrier leads to disruption of the epidermal Ca
gradient, and that re-establishment of this gradient precedes barrier restoration (139, 147).
Further, diseases which disrupt the epidermal barrier, such as psoriasis, or experimentally
induced essential fatty acid deficiency show corresponding loss of this Ca gradient (167,
168). In utero, the Ca gradient is established alongside fetal barrier formation (146).
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However, mechanistically this barrier is poorly understood. The epidermis is replete with
membrane-associated Ca transporters which could export Ca released from the
endoplasmic reticulum (ER) to the extracellular compartment (169). Elias et al. showed
through the artificial re-establishment of barriers in barrier-disrupted tissues exposed to
cold that energy-free, passive mechanisms such as transcutaneous water flow were
sufficient to establish this Ca gradient (139). In fact, studies in two-photon microscopy
showed that the majority of this extracellular Ca originated in the intracellular
compartment, having been released from the ER or Golgi into the cytoplasm (170).
Concentrations of extracellular Ca that promote epidermal differentiation are
associated with increased intracellular Ca (163, 164) produced by Ca binding to the CaR
and inducing a conformational change that leads to Gαq-dependent activation of PLCγ
(165). PLCβ then cleaves phosphatidyl-inositol 4,5-bisphosphate (PIP2) in thecellular
membrane to form the second messengers inositol trisphosphate (IP3) and diacyl-glycerol
(DAG). (10). DAG activates PKC (166) and IP3 releases Ca from intercellular stores
(165). Intracellular calcium can also be elevated through the opening of Ca-gated
outwardly rectifying chloride channels which depolarize the cell causing voltage-gated
Ca channels in the ER to release Ca into the cytoplasm (234-236).
Elevated Ca causes genomic effects (125) such as increases in expression of
markers of differentiation (149), and morphological changes such as cornification (150).
High extracellular Ca also has non-genomic effects on cellular homestasis such as
redistribution of DP, a desmosomal protein that anchors intermediate filaments in
desmosomes to the membrane (140) and increased cell-cell adhesions (15), both of which
are important in establishing and maintaining epidermal barrier function (115, 159, 160).
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Ca is also required for the activation of differentiation-related Tgm1 which crosslinks
proteins in the CE (107) and the activation of matrix metalloproteinases (MMPs) which
cleave membrane-associated ligands and are required for cell motility (171).
The EGF Receptor: A target for regulation by TCDD and Ca
It would be easy to argue that TCDD builds upon the differentiation-inducing
mechanisms similarly affected by increased intracellular Ca. However, keratinocyte
commitment to differentiation is represented not only by genetic, structural, and
morphological changes to the cell, but also by the attenuation of EGFR signaling, a
common regulatory target for both Ca and TCDD. Within the epidermis, the EGFR is the
major driver of epidermal proliferation (172). Studies have shown that EGFR signaling is
strong in basal keratinocytes and is inhibited by Ca in suprabasal layers (173). This is
accompanied by the decreased staining and [125I]-EGF binding capacity observed in the
suprabasal layers of the epidermis (174-176) and indicates that keratinocyte
differentiation is dependent upon both enhanced extracellular Ca and attenuation of
EGFR signaling (177, 178). Secretion of EGFR ligands, such as TGF-α, AREG, or
EREG, are frequently enhanced in hyperproliferative skin disorders such as psoriasis or
atopic dermatitis (145, 179, 180) and experimental overexpression of EGFR ligands can
replicate psoriatic phenotypes (176, 181). Further, juxtacrine signaling by surfaceassociated EGFR ligands maintains differentiated keratinocyte phenotypes while MMPmediated cleavage of these ligands drives keratinocyte migration in wound healing (182).
Work from our lab has shown that EGF, the prototypical ligand for the EGFR,
upregulates nearly 3000 genes in keratinocytes, many involved in processes of epidermal
disease (172). Further, pretreatment with EGF decreases the expression of markers of
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keratinocyte differentiation in vitro and enhances transepithelial water loss (TEWL)
indicative of impaired barrier function and dedifferentiation (172). Pre-treatment with
EGF inhibited TCDD-induced increases in expression of markers of keratinocyte
differentiation, suggesting EGFR signaling is important not only in promoting
keratinocyte proliferation but in suppressing differentiation (6).
Structure and Function of the EGFR: The EGFR is a 170-kDa protein that is a
member of the ErbB family of Type I RTKs in which each ErbB possesses different
ligand affinities and subtly different downstream signaling events (183). All four ErbB
receptors are structurally related and have three domains: an ecto-domain, a
transmembrane domain, and a C-terminal intracellular tyrosine kinase domain (184). The
receptors, while structurally similar, have very different sequences: the EGFR and ErbB2
are the most closely related with 49% identity (64% similarity). In contrast EGFR/ErbB3
have 37% identity (53% similarity) and EGFR/ErbB4 have 28% identity (49%
similiarity) (184). The tyrosine kinase domain is the most conserved between receptors
(39-81% identity) and the C-terminal domain (CTD) the area of lowest identity (12-30%)
(184) (Figure 4).
Work in keratinocytes addressing ErbB signaling tends to focus on the EGFR.
Keratinocytes also express ErbB2, and ErbB3 both in vivo and in vitro (185). The EGFR
is expressed most strongly in the stratum basale and stratum spinosum where cells are
actively proliferating, but is also present in the upper layers of the epidermis (185, 186).
ErbB2 and ErbB3 are found in multiple cell lines and embryonic skin at low levels (185,
186). Stoll et al. identified ErbB2 in the cytoplasm of keratinocytes in the stratum basale,
and on the surface of cells in the stratum granulosum and stratum corneum in sections of
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Shc

Grb2
PI3K

Cbl
STAT5
PTP-2c
Crk

Nck
Src/Csk

SH3BGRL

Figure 4. Phosphotyrosine sites on the ErbB receptors and their effector
molecules. The scaffolding and adaptor molecules Shc and Grb2 can bind on
multiple sites across all four receptors, while other signaling and effector
molecules show far more specific receptor recognition. The E3 ubiquitin ligase
Cbl which leads to receptor ubiquinylations only recognizes phosphorylated
EGFR and PI3K binds on ly ErbB3 and ErbB4 . Src/Csk and STAT5 recognize
ErbB3 and EGFR respectively. The adaptor proteins Crk and Nck recognize
phosphotyrosine residues on ErbB4 and are thus not relevant to epidermal ErbB
signaling in skin (186). SH3BGRL, an SH3/SH2 domain containing protein, and
protein tyrosine phosphatase 2C (PTP-2c) bind EGFR and ErbB2. Figure adapted
from (187). Abbreviations: Ligand-binding domain (LBD), Tyrosine kinase (TK)
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human skin and A431 keratinocytes in vitro (185). However, in the MD-MBA breast
cancer cell line which expresses higher levels of ErbB2, smaller, cuboidal “basal-like”
cells expressed a mixture of surface and punctate intracellular ErbB2, suggesting that the
relative amount of ErbB receptors present in a system can drive alterations in cellular
localization and recycling of active ErbB receptor (185). Similar observations were made
regarding EGFR in vivo or in EGFR-overexpressing A431 cells in vitro (185). ErbB2,
which lacks a ligand binding domain but possesses a constitutively active tyrosine kinase
domain, has been shown to enhance tumor promotion by phorbol esthers in murine
epidermal overexpression models (187). Further, due to its suprabasal expression,
ErbB1/ErbB2 heterodimers are thought to play a role in ligand-induced differentiation
while signaling through ErbB1 homodimers functions to drive proliferation and migration
(185). This may reflect the tendency of ErbB heterodimers to recycle causing a more
persistant EGFR signal as opposed to the shorter signaling induced by EGFR
homodimers. ErbB3’s role in skin is poorly understood but it does appear to be important
in melanocyte development, and plays a role in melanoma progression (188). ErbB4 has
not been shown in the epidermis, keratinocyte monolayer or organ culture, or
keratinocyte cell lines (185). In normal human keratinocytes in monolayer culture,
ErbB2 and ErbB3 receptor numbers increase as cells become confluent, suggesting that
ErbB2 and ErbB3 serve to maintain tissue structure and differentiation but also allow for
a rapid response to wound regeneration wherein the loss of cell-cell contact changes
EGFR signal from predominantly juxtacrine activation by membrane bound pro-EGFR
ligands to paracrine activation by soluble ligands. (189).
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Across the ErbB family, phosphorylation of tyrosine residues in the CTD recruits
signaling and adaptor proteins to the receptors. This allows signaling molecules as well as
scaffold and adaptor proteins to interact with receptors via their SH2 or phosphotyrosinebinding (PTB) domains (190). The low degree of sequence identity within the CTD of
ErbB receptors, contributes to distinctive signaling activity associated with each ErbB
receptor and ErbB receptor dimers (Table 4). The EGFR has several sites which
associate with Grb2, Stat5, and Shc, as well as sites for c-Cbl, a ubiquitin ligase which
target receptors for internalization (191). ErbB2 interacts primarily with Shc leading to
Ras-dependent extracellular signal-related kinase (ERK) activation, but also protein
kinase A (PKA) (192). In murine models and human skin cancers, elevated ErbB2 is
strongly linked to tumor promotion and neoplasm, respectively (187, 192, 193) while
ErbB3 and ErbB4 are the only members of the ErbB family that can interact with the p85
subunit of PI3K (191, 194).
Upwards of 20% of the EGFR protein is N-glycosylated, which targets it to the
plasma membrane where it exists as an inactive monomer, or transiently, as a dimer
(184). Localization of the EGFR to the membrane increases its effective concentration
and makes dimerization more likely (195). However, evidence also exists to support the
presence of pre-formed dimers which dissociate upon ligand binding (196). Though these
preformed homo- and heterodimers are thought to be largely inactive (197), their
existence allows for more rapid activation of ErbB receptors and a higher degree of
phosphorylation of cellular ERK and Akt following EGF challenge (198). Over half of
the EGFR found in caveolae exist in their unphosphorylated state, but the readily
available pool of potential dimer partners and effector molecules enhances receptor
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Table 4. Common ErbB phosphorylation sites.

Site
Y845
Y992
Y1045

Phosphorylated by
Src
Auto/transphosphorylation
Auto/transphosphorylation

Y1068
Y1086
Y1148
Y1173

Auto/transphosphorylation
Auto/transphosphorylation

EGFR
EGFR Recruits
Stat5, P38
PLCγ, SHC
c-cbl

Activates
Ras, Stat5
Stat3, PKC, Erk, Vav2
Ubiquitinylation

Autophosphorylation

Grb2, JNK
Grb2, SH2
Shc
Shc

Ras, Stat3, c-Jun, AP-1
Stat3, MAPK, Pak1
MAPK, Stat1, AP-1
MAPK, PLCγ, Shp2

S1046/7

Cam Kinase II

P38

S1070

Cam Kinase II

c-Cbl

c-Cbl independent
internalization
Internalization &
ubiquitinylation

Site
Y877
Y1112
Y1221/2
Y1248
T686
S1113

Phosphorylated by
Src
Auto/transphosphorylation
Auto/transphosphorylation
Auto/transphosphorylation
PKC
Calmodulin Kinase II (CaMK II)

ErbB2
ErbB2 Recruits
c-cbl

Activates
Stat3, PKA
Ubiquitinylation & degradation
Shc, ErbB2
ErbB2
Internalization

Reference
(211-213)
(212, 214) (215-217)
(208, 208, 208, 218,
219)
(212, 218, 220, 221)
(212, 216, 217)
(212, 215, 222-224)
(212, 215, 222224)(225)
(225-227)
(209, 225, 226)

Reference
(192)
(228, 229)
(190, 223, 230-232)
(230, 231)
(233)
(234)

ErbB3
Site
Phosphorylated by
ErbB3 Recruits
Activates
Reference
PI3K
PI3K, Akt
(194)
Y1289
Abbreviations: Mitogen activated protein kinase (MAPK), Y= tyrosine, S=serine, T=threonine, Calmodulin Kinase II (CaMK II)
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responsiveness by facilitating dimerization and transactivation at the membrane rafts
(199).
Upon ligand binding, receptor dimerization is induced by changes in
conformation of the ligand-bound ectodomain and the exposure of the dimerization loop.
While all 10 dimeric configurations of ErbB receptors are possible, some heterodimers
are preferred (175, 200). ErbB2 lacks a ligand-binding domain, resulting in the
constitutive exposure of its dimerization domain and making it the preferred dimerization
partner for the all ErbBs (201). More, EGFR/ErbB2 heterodimers decrease EGFR
degradation while EGFR homodimers are sorted more rapidly to the lysosome for
receptor degradation (202, 203). Receptors dimerize and transphosphorylate one another
(204) which allows signaling molecules, scaffolds, and signal inactivators to bind via
SH2 and PTB domains.
Following dimerization, phosphorylation of two regions of the CTD targets the
EGFR to clathrin-coated pits where it is rapidly internalized into endosomes (203, 205207). From here, ligand either remains bound to the receptor and the ligand-receptor
complex is degraded, or it is released and the receptor is recycled to the surface (Figure
5; 202). EGFR homodimer sorting to the lysosome is directed by multiple monoubiquitinylation (208, 209). While the process is not fully understood, receptor
endocytosis appears to be cholesterol-dependent and concentrated at lipid rafts (202,
206). Clathrin-mediated endocytosis, conversely, leads to a higher rate of EGFR
recycling to the surface prolonging the ability of EGFR to signal (210). This non-clathrin
endocytosis drives receptor sorting to lysosomes and is more likely to attenuate EGFR
signaling (184, 210).
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Figure 5. ErbB subtypes and ligand specificity, signaling, and trafficking.
The top left portion of this figures shows the four ErbB receptor subtypes
(ErbB1-4) and differential ligand specificities. ErbB2 lacks a ligand binding
domain and ErbB3 lacks a tyrosine kinase domain (2, 184). Ligand binding
promotes dimerization, phosphorylation, and ubiquitinylation of the ErbB
dimer. This targets it for association with effectors promoting ErbB-mediated
signaling as well as targeting the dimer for internalization in clathrin-coated pits
(52, 118, 203, 234). In endosomes, ligand identity and dimer composition direct
receptor recycling versus degradation (183).
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Heterodimers of EGFR/ErbB2 or EGFR/ErbB3 tend to dissociate from the ligand
regardless of ligand identity and are recycled back to the surface giving heterodimers a
stronger and more persistent signaling capacity than EGFR homodimers (202). However,
while receptor dimer pairs and method of endocytosis can dictate receptor degradation or
recycling, ligand can also play a role. EGF causes downregulation of EGFR homodimers
while other ligands, such as TGF-α, direct recycling of the receptor to the surface (205,
235).
Location-Dependent EGFR Signal Transduction and Down-regulation:
EGFR signaling activates pathways involved in proliferation, cell survival and migration
and its activity must be inhibited in the course of normal keratinocyte differentiation
(175, 236). Although phosphorylated EGFRs in endosomes have lost access to ligands,
these receptors can still signal, While EGFRs cannot associate with or activate PLCγ or
PI3K whose substrates are located in the plasma membrane (199, 222), the receptors
remain phosphorylated and associated with the scaffolding protein SHC (src homology 2
containing containing transforming protein 1), the adaptor protein Grb2 (cytoplasmic
growth factor receptor bound protein 2 ), or the guanine nucleotide exchange factor SOS
(son of sevenless homolog 1), all of which allow ERK signaling to be propagated (237).
These changes in location-dependent signal transduction can have profound
effects on keratinocyte cell fate. EGFR signaling is canonically considered to be
proliferative in keratinocytes, and ERK activation is also linked to keratinocyte
proliferation and hyperproliferation in disease states (238-240). Previous studies have
shown that PLCγ activation is required for keratinocyte differentiation (11) and that
distribution of PLCγ is frequently altered in hyperproliferative skin conditions such as
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psoriasis or seborrheic keratosis (241). PLCγ can be directly activated by EGFRdependent phosphorylation and is also activated in a PI3K-dependent manner involving
Ca-, c-src-, and cadherin-dependent mechanism (11, 242). PI3K sits upstream of PLCγ in
keratinocytes but can also signal through Akt to promote keratinocyte differentiation and
prevent cell death (242). As discussed previously, ErbB3 is the only ErbB receptor in
keratinocytes with a binding site for PI3K, a pro-differentiation signaling cascade in
keratinocytes (191). Thus through differentiation-induced changes in ErbB receptor
complement that cause a suprabasal increase of ErbB3, the EGFR could switch from proproliferative signaling to pro-differentiation signaling, dependent upon context.
MAPK/ERK pathway: Five members of serine/threonine MAPKs have been
classified to date: ERK 1/2, c-Jun amino terminal kinases (JNK), p38, ERK 3 and 4, and
ERK5 (243). Each MAPK pathway consists of a MAPKK kinase (MAPKKK) that
activates a dual specificity MAPK kinase (MAPKK) which in turn activates a mitogenactivated protein kinase (MAPK) by phosphorylation of tyrosine and threonine residues.
The ERK signaling cascade is one of the primary mitogenic pathways in the epidermis,
and a pathway that can be activated by all receptor tyrosine kinases. Activation of the
ERK pathway is initiated by phosphorylation of growth factor receptors including those
for EGF, platelet derived growth factor (PDGF), insulin-like growth factor 1(IGF1),
fibroblast-derived growth factor (FGF), and dermally-secreted keratinocyte growth factor
(KGF / FGF7) (244).
In the ERK 1/2 pathway (Figure 6A), EGF-like ligands activate the EGFR,
inducing dimerization and transactivation of ErbB dimer pairs. The phosphorylation of
tyrosines such as Y1068 and Y1086 on EGFR, recruit Grb2 via its SH2 domain (217,
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220). The SH3 domains of Grb2 bind the guanine nucleotide exchange factor, SOS,
which activates a membrane-associated GTPase, Ras (244). Activated Ras interacts with
a downstream effector, Raf, the MAPKKK of the RAS-RAF-MEK-ERK pathway (243).
Raf then phosphorylates the dual specificity kinases MAPK/ERK kinases (MEK), MEK1
and 2, which in turn activate ERK 1/2 (243).
Phosphorylated ERK that is not associated with scaffolding molecules can move
into the nucleus where it is a major modulator of cellular proliferation and involved in
entry into the G1 phase of cell cycle (245). Activated ERK phosphorylates over 80
downstream effectors including nuclear substrates and transcription factors such as AP-1,
c-Myc, c-Fos, STAT3, and Pax6. ERK also phosphorylates cytoskeletal and membraneassociated proteins such as CD120A, Syk, and Calnexin which alter keratinocyte
cytoskeletons to allow suprabasal migration (246). The localization of ERK signaling can
also influence which interacting partners are able to interact with the receptors. With the
loss of juxtacrine signaling in wounding, EGFR dimers can be internalized, and signal
through ERK at the level of the endosome (237, 247). Conversely, the loss of cytosolic
phosphorylated ERK through nuclear localization can attenuate signaling through
cytosolic proteins maintaining suprabasal phenotype of keratinocytes in the case of an
intact epithelium (238). Cytosolic ERK drives cytoskeletal changes and motility (248).
Changes in ligand-stimulated EGFR activation following wounding and desmosomal
interruption stimulate cytoskeletal changes, allowing for migration of keratinocytes
across the wound (182, 240). ERK can also lead to activation of other proteins which lead
to cytoskeletal or transcription factor phosphorylation such as Rsk2 and MSK1 (249).
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In the epidermis, the ERK pathway plays an important role in regulating normal
epidermal homeostasis, as well as keratinocyte proliferation and viability (238). Increases
in ERK activity associated with activating mutations of Ras or Ras over-expression occur
in the majority of human squamous cell carcinomas (SCC) and is a key player in the

Figure 6. Signaling Pathways downstream of the EGFR. The EGFR upon
activation will dimerize and is capable of interacting with several downstream
pathways involved in cell proliferation, differentiation, and survival. Three
prominent pathways are (A) RAS/RAF/ERK (B) PLCγ and (C) PI3K. PKC
which is stimulated indirectly by EGFR activation also provides feedback
inhibition to the EGFR

development of murine SCC models (238). In the epidermis, Ras is activated in basal
layers to drive proliferation while the Ras protein is lost suprabasally (250). Within the
normal epidermis, Ras overexpression or hyperactivation of the RAS-RAF-MEK-ERK
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pathway in basal layers leads to epidermal hyper-proliferation and thickening, as well as
impaired differentiation (250).
Phospholipase Cγ/Protein Kinase C: PLCγ is a membrane-associated enzyme
that cleaves PIP2 into IP3 and DAG. While both function as second messengers
interacting with downstream pathways, DAG remains membrane- associated while IP3
diffuses into the cytosol where it interacts with IP3 receptors in the ER and releases
calcium into the cytosol. Ca, along with DAG activate classical PKCs (α, β, and γ) while
DAG alone is required for activation of novel PKCs (ε, η, δ, and θ) (251). PKC is a
serine/threonine kinase which has a number of substrates and is capable of
autophosphorylation (252). PKC is thus activated by and linked to increased intracellular
Ca and phosphorylates the EGFR on T654, which causes its downregulation (253, 254).
PKC (Figure 6B) is also linked to Ca-driven structural changes such as enhanced
desmosome formation (252). PKC α is activated by DAG and Ca and phosphorylates DP,
a required part of the desmosome which anchors intermediate filaments to desmosomal
plaques (255). DP phosphorylation by PKCα is required for desmosomal formation (256),
but loss of PKCα seems to be necessary for the dissolution of desmosomes preceding
epithelial-mesynchymal transition (EMT) in wounding (257).
In the normal epidermis, membrane-associated PLCγ co-localizes with the EGFR
only in the basal compartment. In contrast, suprabasal expression of PLCγ is common in
many epidermal hyperproliferative diseases such as psoriasis, seborrheic keratosis, and
the margins of second degree burns (241). However, PKC co-localizes to desmosomes in
murine and human epidermis and serves to maintain epidermal barrier function in the
intact epidermis (130, 250). The expression and activation of certain isoforms,
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particularly PKCη, but also PKCα and δ, have been shown to be necessary for the
expression of differentiation markers such as Lor, Ivl, SPRR-1, and Flg as well as the
initiation of the differentiation process (258, 259).
Phosphoinositide-3 Kinase signaling: There are three classes of
phosphoinositide-3 kinases (260). The most commonly studied are class I PI3Ks which
are targets for activation by RTKs and G-protein coupled receptors (GPCRs) (260). Class
I PI3Ks phosphorylate PIP2 to PIP3 at the cellular membrane while classes II and III are
less well understood and thought to be involved in vesicular signaling (261, 262). Class I
PI3Ks are heterodimeric molecules comprised of a 110 kDa catalytic subunit and an 85
kDa regulatory subunit containing a p110-binding region as well as two SH2 sites (260).
Class I PI3Ks are activated by ErbB3 and ErbB4 (261).
Evidence shows that PI3K/Akt is activated by the EGFR or c-Src in early
epidermal differentiation both in vivo and in vitro (185, 242). However, the role of PI3K
in epidermal homeostasis is complicated and seems to be highly context dependent. In the
best understood scenario, PI3K signaling promotes cell survival by stimulating Aktdriven inhibition of pro-apoptotic genes (242). Epidermal PI3K also activates PLCγ
through the non-receptor kinases fyn and src, suggesting that PI3K is involved in
epidermal differentiation (262). However the role of PI3K may not be so much of an onoff switch, as a context-dependent pro-survival and differentiating signal.
While PI3K deletions in mice cannot be studied as they are early embryonic lethal
(263), mice lacking phosphatase and tensin homolog (PTEN) which inactivates PI3K
signaling, display a “shaggy bear” phenotype characterized by wrinkly skin and fur
symptomatic of hyperkeratosis, hyperproliferation, and hypergranulation. These data
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suggest that an unregulated increase in PI3K promotes aberrant proliferation (263), a
hypothesis supported by data in the HaCaT human keratinocyte cell line where PI3K
overexpression leads to increased invasiveness and epidermal thickening in organotypic
culture (263). In addition, constitutive activation of PI3K inhibits the expression of
markers of differentiation while driving hyperproliferation, leading to disorganized,
hyperplastic, and poorly differentiated tissue (263, 264).
This contextual signals driving differentiative and anti-apoptotic responses as
opposed a proliferative, migratory role in the epidermis makes sense, within the context
of wound healing and EGFR internalization. While both the p110 α and β catalytic
subunits of PI3K are strongly expressed in the skin, the basal activation of Akt in normal
skin is limited to the hair follicle sheath, the basal layer of neonatal murine epidermis,
and extensively in the wounded epidermis where it stimulates cytoskeletal rearrangement
to allow for EMT and keratinocyte wound infiltration (242, 263). Wounding leads to a
rapid increase of phospho-Akt, particularly during the inflammatory phase of wound
healing, but also leads to the upregulation of the p110 γ catalytic subunit of PI3K perhaps
suggesting that enhanced Akt phosphorylation reflects an upstream increase in PI3K
activity (263).
Although the role of PI3K is still emerging, it appears to inhibit apopostis while
maintaining a degree of epidermal plasticity for the skin’s healing response (242, 263).
Stimulation of PI3K is tied to differentiation, both through location and ErbB receptor
subtype. Due to its colocalization with membrane phospholipids, Class I PI3K is
associated with signaling from the membrane (261). It clusters to TJ and desmosomal
structures at the membrane and thus readily activates and is activated by ErbB receptors
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colocalized to these same structures. Activation of PI3K by juxtracrine-activated EGFR
at desmosomes can serve as a presence/absence indicator of cell-cell contact which is lost
following desmosomal disruption. This leads to enhanced activation and altered PI3K
signaling upon disruption or wounding (10, 260, 265). Further, only ErbB dimer pairs
containing ErbB3 or ErbB4 can signal through PI3K (183). However, ErbB4 is not
expressed in the epidermis suggesting that EGFR-ErbB3 dimers drive PI3K signaling in
the epidermis (185).
EGFR Ligands
EGF and its family of ligands (Table 5) are formed as membrane boundpromolecules containing one or more EGF-like domains (176). Of the 11 ligands in the
EGFR ligand family, the EGFR recognizes the most ligands including EGF, TGF-α,
betacellulin (BTC), heparin binding EGF-like growth factor (HB-EGF), epiregulin
(EREG), amphiregulin (AREG), and epigen (EPGN) (266). In addition, BTC, HB-EGF,
and EREG bind to ErbB4 (175, 267). ErbB2 possesses no ligand-binding domain and
thus recognizes no EGF-like ligands while neuregulins (NRG) 1-4 bind to ErbB3 and
ErbB4 (268). Since EGFR signaling promotes proliferation, cell survival, and migration
its signaling capacity must inhibited in the course of normal keratinocyte differentiation
(175, 236). The epidermis contains EGFR, ErbB2, and ErbB3 which can recognize all
EGFR ligands and signal through EGFR/ErbB2 and EGFR/ErbB3 heterodimers as well
as EGFR/EGFR homodimers (197).
EGFR ligands in the skin auto-induce their own mRNA as well as cross-induce
that of other EGFR ligands (279-281). For TGF-α, this occurs through a PKC-dependent
stabilization of the TGF-α transcript that increases the half-life of its mRNA in primary
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Table 5. Properties of EGFR ligands and their role in the epidermis.
Ligand

Size
(kDa)

ErbB
Bound
(269)
EGFR

EGFR
Kd

TCDD-induced
mRNA

Role in the epidermis

Reference

AREG

11.3

4.24

NC

(211-213,
269)

9.0

EGFR,
ErbB4

1.43

NC

EGF

6.2

EGFR

1.83

NC

EPGN
EREG

7.9
6.0

EGFR
EGFR

26783
UNKN

+3.77-fold
+2.02-fold

HB-EGF

9.7

6.83

NC

TGF-α

5.2

EGFR,
ErbB4
EGFR

8.82

+1.71-fold

Epidermal proliferation, wound healing,
inflammatory response, over-expression
causes psoriatic-like lesions
hair follicle development and hair cycle,
but KO or over-expression models have no
skin phenotype
Used historically in skin literature, but not
produced in the epidermis
Causes sebaceous hyperplasia in utero
Loss of EREG causes chronic dermatitislike phenotype
Involved in wound healing and
keratinocyte migration
Elevated in many hyperproliferative skin
diseases, KO causes a wavy hair
phenotype

BTC

(269)

(3, 175, 270)
(111, 271)
(272)
(182, 273)
(179, 270,
274, 275)

Abbreviations: No measured binding (NMB), No change (NC). 1molecular weight of pro-ligand 2solubilized full length EGFR in
A431 cells 3As competitive binding experiments for EGFR ligands are performed in a heterogeneous system, Kd have been calculated
from IC50 utilizing the Cheng-Prusoff equation (276): 𝐾𝑑 = 𝐼𝐶50 ⁄(

(1+[𝑐𝑜𝑚𝑝𝑒𝑡𝑖𝑡𝑜𝑟])

EGF (278).
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(𝐾𝐷𝑐𝑜𝑚𝑝𝑒𝑡𝑖𝑡𝑜𝑟 )

) for 50 pM [125I]-EGF (277) 4or 645 pM [125I]-

keratinocytes (8, 282, 283). In other systems, such as the transformed colon epithelial
LIM1215, auto-induction occurs through an EGFR-dependent transcriptional mechanism
(282). In both cases, inhibition of the EGFR or PKC reverses the increase in TGF-α
mRNA (282). Similar increases in BTC mRNA levels were observed in RIE-1
gastrointestinal cells, however increases in secreted AREG and HB-EGF were only
partially explained by a transcriptional mechanism (283). AREG and HB-EGF were also
found to be elevated in cell lysates and conditioned medium before other EGFR ligands
suggesting a role in promoting synthesis of other EGFR ligands (283). This suggests that
increased cleavage as opposed to, or in conjunction with, increased synthesis drives
increase of some ligands.
EGFR ligands are released at different times, to different degrees, and have
differential downstream effects following ErbB receptor activation (284). In
keratinocytes, AREG is strongly proliferative, and in conjunction with HB-EGF, can
account for around 70% of proliferation in monolayer keratinocytes grown in the absence
of EGF (285). However, in mammary cell lines, AREG was the only assayed EGF-like
ligand that failed to induce proliferation or increase ErbB3 phosphorylation (284). Other
ligands, such as TGF-α, are not observed at a high level in normal skin, but are elevated
in response to toxin exposure or epidermal disease (7, 274, 282). Overall, AREG, HBEGF, TGF-α, and EREG are secreted by normal keratinocytes or upregulated in
epidermal hyperproliferative diseases (196).
Competition assays show that EGFR ligands possess markedly different affinities
for the EGFR. However, these data must be interpreted cautiously, as most assays have
used [125I]-EGF instead of iodinated forms of the ligand in question (270, 278). In
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addition, each ligand possesses a different functional EC50 for proliferation, cell motility,
and the EGFR signaling pathways they activate. While all EGF ligands in keratinocytes
bind exclusively to the EGFR (176, 286), each ligand preferentially stabilizes differing
ErbB dimer pairs which can have implications in endocytic sorting and receptor
downregulation (176, 286). ErbB2, the preferential dimer partner for EGFR, raises the
EGFR’s affinity for TGF-α and HB-EGF (270), making ligand binding to EGFR/ErbB2
dimer pairs more likely than EGFR homodimers. Further, the presence of a heparin
binding domain like that possessed by AREG and HB-EGF lowers the affinity of these
ligands for the EGFR (288) though enhances acid-resistance to the low pH in lysosomes,
directing receptors to degrade as opposed to TGF-α which dissociates at a low pH and
leads the receptors to recycle (287).
EGFR ligands are produced and trafficked to the cell surface in a membraneassociated pro-form (171). From the membrane, ligands can signal directly with
neighboring cells in a juxtacrine manner or can be cleaved by Ca-dependent
metalloproteinases to interact with receptors on the same (autocrine) or neighboring
(paracrine) cells (Figure 7) (171, 269). This provides a mechanism for changes in EGFR
signaling following disruption of cell-cell contact in wounding, and as a mechanism of
altering EGFR signaling in differentiation (182, 289). Juxtacrine signaling does not allow
for receptor endocytosis as the membrane-tethered ligand prevents internalization (171).
This keeps the EGFR at the surface where it can signal through PI3K and PLCγ (289,
290). Overall EGFR signaling represents a highly evolved system with a high degree of
combinatorial complexity. In the epidermis, four ligands are secreted which can activate
three ErbB receptors, producing five functional dimer pairs. These dimers can signal
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persistently at the cell surface, or inside the cell, and can activate a number of different
downstream signaling pathways . This allows for the temporal and spatial control of
EGFR signaling that is critical for epidermal homeostasis but still not fully understood
(291).

A

MMPmediated
cleavage

ProAREG

AREG

AREG

B

C

Figure 7. Mechanisms of EGFR activation for EGF-like ligands. ProAREG (or another EGF-like ligand) exists in a membrane-bound form wherein
it can activate EGFRs on neighboring cells in a (A) Juxtacrine manner, or,
following cleavage by MMPs or ADAMs, diffuse in its cleaved form to
activate EGFRs in an (B) autocrine or (C) paracrine fashion. Adapted from
(182)

EGF—the prototypical EGFR ligand: As the nomenclature suggests, EGF is
the prototypical EGFR ligand and the first EGFR ligand identified (205, 292, 293). EGF
has a high affinity for the EGFR and upon binding, induces dimerization and lysosomal
degradation following internalization (204, 294). EGF is the best understood EGFR
ligand and its frequent use has led to the preferential development and availability of
tools specific to this ligand. These facts have led to a historical tendency to use EGF as an
equivalent for other ligands in studying the EGFR in systems such as keratinocytes (7,
48

295). Choi et al. (8) identified TGF-α in conditioned medium and then used [I125]-EGF to
study TGF-α induced EGFR downregulation. However, differences in affinity, structure,
and endosomal sorting of ligands and receptors create a false equivalency, particularly in
the epidermis which does not produce soluble or membrane bound EGF (3, 176). Further,
EGF binds to and down-regulates EGFRs differently than other ligands such as TGF-α
which causes rapid receptor cycling, or AREG which causes slow recycling (287).
Amphiregulin (AREG): In humans, AREG expression is controlled by two
copies of the AREG gene, AREG and AREGB which are found on chromosome 4q13.3
and flanked by BTC on the 3’ end and EPGN on the 5’ end (296). These genes produce a
1.4 kb, six exon product which is translated into a 252 amino acid pro-form of AREG
(296). This pro-AREG contains five major domains, including a signal domain (aa 1-19),
an N-terminal domain (aa 20-101), an EGF-like domain (aa 102-184), a transmembrane
domain (aa 199-221) and a cytoplasmic tail (aa 222-252) (297). Pro-AREG is cleaved by
a disintegrin and metalloproteinase (ADAM)17, ADAM15, and MMP1(298-301).
Proteolysis results in a 98 amino acid soluble AREG with a molecular mass of 11.3 kDa.
AREG is typically referred to as a low affinity ligand for the EGFR, even though its IC50
in competitive binding assays is within the same order of magnitude as most other ligands
(278). This description appears to arise from the observation that AREG is far less potent
than EGF in stimulating receptor phosphorylation or colony formation, in some cases
requires 300 times as much ligand (270, 278). AREG, like EGF, remains associated with
the EGFR in the late endosome. While it does not target the EGFR for lysosomal
degradation, it does cause a slower recycling of the EGFR back to the cell surface (~30
minutes) compared to TGF-α (2-5 minutes) (287).
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TCDD does not affect AREG production in the skin but does increase its
production in murine ureters (104) and by tobacco smoke in human oral mucosal cells
(302) . When experimentally overexpressed in murine skin, AREG caused a psoriatic
phenotype characterized by epidermal thickening and severe, early-onset psoriasis when
overexpression was targeted to suprabasal keratinocytes (181, 303). In the latter case,
AREG overexpression was involved in the induction of synovitis, suggestive of a
mechanism of psoriatic arthritis, a common co-morbidity to psoriasis (181, 304). In
humans, AREG is an autocrine growth factor for keratinocytes, enhancing ErbB1mediated ERK signaling and proliferation (145, 182, 240).
In cultured human keratinocytes, AREG mRNA expression was 19 times greater
than any other EGFR ligand and soluble AREG was present at 7.5 times the
concentration of any other EGFR ligand. AREG drives keratinocyte proliferation in an
EGFR and CTD-dependent manner (182, 297, 305). Further, AREG is upregulated in
human epidermal diseases such as psoriasis and squamous cell carcinomas of the
epidermis, reinforcing its role in hyperproliferative conditions (306).
Heparin Binding EGF-like Growth Factor (HB-EGF): In humans, proHB-EGF
is a 21 kDa protein first isolated from macrophages (289, 307) and biochemically
characterized by Iwamoto (289, 307). Structurally similar to AREG, HB-EGF is found
on the minus strand of chromosome 5q23 which encodes an 87 amino acid protein
comprised of five exons (279). Interestingly, Pro-HB-EGF is unique among EGFR
ligands in that it serves as a receptor for the diphtheria toxin. (308). Pro-HB-EGF is
targeted to the cell membrane where it can signal in a growth-inhibitory juxtacrine
manner at points of cell-cell contact. However, when cleaved by MMP-3, MMP-7 (309,
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310) or MMP1 it becomes soluble and stimulates keratinocyte motility (298). HB-EGF is
a low affinity ligand containing a heparin binding domain (311) and it is heavily Oglycosylated. Like AREG, HB-EGF possesses a heparin-binding domain that makes it
acid resistant and less likely to dissociate in the late endosome (287). However, unlike
AREG, HB-EGF leads to EGFR downregulation by targeting endocytosed receptors to
the lysosome for degradation rather than slow recycling (203, 312)
Experimentally induced injuries lead to MMP-mediated cleavage of HB-EGF,
producing its soluble form. Soluble HB-EGF stimulates not only proliferation like
AREG, but is also involved in migration and EMT (182, 313). In human skin, pro-HBEGF is responsible for cell-cycle inhibition and maintaining an epithelial phenotype
(288). When HB-EGF is cleaved, the soluble HB-EGF enters the extracellular space and
the CTD of HB-EGF enters the cytoplasmic where it alleviates transcriptional repression
of cell cycle by promyelocytic leukemia zinc finger protein (PLZF). In fact, localization
of the CTD correlates with cell cycle phase: cytoplasmic in early G1, nuclear in S phase
(preceding late S phase transport of PLZF), and near centrosomes during cytokinesis. In
this manner, cleaved HB-EGF serves not only to mitogenically signal to neighboring
cells in autocrine/paracrine fashion following wounding, its CTD also drives proliferation
in the secreting cell (314). Meanwhile prolonged juxtacrine signaling inhibits this CTDdriven cell cycle progression (314). HB-EGF also protects the cell from anoikis, a
specialized form of apoptosis that occurs when cells lose contact with their basement
membrane, allowing the cells to instead undergo cornification (171, 288). In normal and
psoriatic skin, HB-EGF is expressed diffusely in all layers, though co-localization with
ErbB3 increases in the stratum granulosum and stratum corneum, leading to an increased
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activation of PI3K through EGFR-ErbB3 heterodimers, enhanced cell longevity, and
epidermal thickening (145).
Transforming Growth Factor-Alpha (TGF- α): TGF-α is a high affinity EGFR
ligand that causes rapid EGFR recycling (287). In the epidermis, TGF-α is expressed in
the basal, spinous, and granular layers (275). The human TGFA gene is located on the
minus arm of chromosome 2p13. The 106,914 base pair transcript is translated into a 160
amino acid, 17kDa protein comprised of 6 exons with tissue-dependent splice variants
(274). TGF-α is cleaved by tumor necrosis factor-alpha converting enzyme
(TACE/ADAM17), MMP1and ADAM10 (315) to create a 5.2 kDa soluble TGF-α (133,
315, 316). Alternately spliced products excluding exon 6, or part of exon 5 and 6 were
elevated in conditioned medium from squamous cell carcinoma cells. These transcripts
were cleaved as readily as wild type TGF-α, but led to enhanced proliferation in both
cancerous and normal keratinocytes (274). TGF-α bound to EGFRs maintains epidermal
signaling capacity by inducing rapid recycling to the cell surface (287).
In mice, loss of TGF-α creates a distinctive phenotype of wavy hairs growing
from irregular hair follicles (317). Knockout mice also display decreased ear wound
healing, but this result was not replicated in other wounding assays (318). Targeted
overexpression of TGF-α causes spontaneous papillomas and epidermal hyperplasia
reminiscent of psoriasis (319). In mice overexpressing TGF-α under a K1 promoter, mice
exhibited increased incidences of epidermal tumorigenesis as well as enhanced sensitivity
to tumor promoting phorbol esthers (320).
TGF-α was the first EGFR ligand whose secretion was reported to be enhanced in
keratinocytes exposed to TCDD (7, 8). Elevated TGF-α is observed in TCDD exposed
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tissues in vivo, including murine palates where leads to cleft palates and urogenitary
tracts (3, 102). Pathophysiologically it is elevated in epidermal hyperproliferative
disorders such as psoriasis and atopic dermatitis in humans (161, 179, 180).
Epiregulin (EREG): EREG is the last EGFR ligand found to be secreted by
keratinocytes (196). Identified in 2000, EREG is located between EPGN and AREG on
chromosome 4q13 (279). The 4.8 kb transcript is translated into a 19 kDa protein
comprised of 169 amino acids (279, 287). EREG is cleaved by TACE and ADAM10
(316), and, like TGF-α, EREG causes rapid receptor cycling following endocytosis (287).
In mice, the loss of EREG led to a late-onset, chronic dermatitis (321). Histological
examination of these plaques and unaffected skin showed epidermal thickening and
increased infiltration of macrophages into the skin (321). Shirasawa et al. posit that
EREG’s role in the skin is to mediate inflammatory response (321) as secreted and
membrane-bound EREG regulate cytokine production by the keratinocyte and
neighboring Langerhans cells (321). However, other work in keratinocytes supports a
strongly mitogenic effect of EREG (322) and it is also upregulated in psoriatic plaques in
humans, frequently accompanied by an increase in AREG and TGF-α (323). In addition,
EREG is upregulated by TCDD in mice (8, 9, 104) which occurs via an XRE-dependent
mechanism in murine keratinocytes. However, this promoter motif is not present in
human cells (9).
Other EGFR Ligands: The remaining six EGFR ligands have limited to no
known role in the epidermis. BTC is secreted from cells in the hair follicle (272, 281).
While this can lead to induction of EGFR ligands in neighboring skin cells in vivo (281)
and has been observed to be increase angiogenesis in wounded skin (272), it is not
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observed in keratinocytes in vitro (272). EPGN similarly has no known role in the
epidermis, but it has been shown to induce sebaceous hyperproliferation in utero (111).
NRG 1-4 have not been observed in skin.
The role of growth factors and exogenous chemicals in epidermal wound healing
The epidermis has a high degree of plasticity, owing to the ability of skin to
respond to damage. In the case of wounding, the epidermal barrier is disrupted, and
importantly, keratinocyte desmosomes and TJs are lost, taking away desmosomally
clustered juxtacrine signaling and leading to the enhanced secretion of growth factors that
drive keratinocyte migration and healing (105, 324). The immediate response of the skin
to wounding is not epidermal barrier repair, but rather, formation of a blood clot.
Polymorphonuclear (PMN) neutrophils are attracted to the clot site and serve an
antibacterial function, releasing antibacterial respiratory burst and phagocytizing debris
(325). After the PMN fulfill their task, dermal and epidermal macrophages phagocytize
them and other damaged or dead cells (325, 326). Over time, macrophages and
monocytes in the wound decrease, allowing for the keratinocyte-driven proliferative stage
of wound healing to begin (327).
As the inflammatory stage of wound healing ends, fibroblasts from the dermis
migrate into the wound site, and re-establish the ECM. Macrophage-secreted cytokines
recruit endothelial cells for angiogenesis (327). Once a solid layer of granulation tissue,
comprised of new blood vessels, fibroblasts, inflammatory cells and the fresh ECM (328)
has developed, the basal keratinocytes are directed by MMP-induced cleavage of growth
factors to migrate across the injured epithelium (329). These EGFR ligands provide a
strong proliferative pressure following the re-establishment of cell-cell contacts.
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Differentiation and reformation of the epidermal barrier follow (329). However, it is the
inherent plasticity of this system wherein EGFR ligands are capable of both maintaining
differentiated state and driving dedifferentiation that is commonly exploited in
hyperproliferative skin diseases.
Epidermal homeostasis and disease
While Ca drives differentiation in keratinocytes, EGFR signaling represents a
powerful and complex proliferative stimulus which must be overcome in order to switch
to a program of terminal differentiation. However, the assumption that Ca-induced
differentiation progresses by silencing the proliferative signaling of the EGFR is too
simplistic. Both EGFR and Ca activate PKC which drives differentiation and, in a
negative feedback mechanism, silences the EGFR (253, 259). Ca is also involved in the
activation of MMPs which cleave pro-EGF like ligands and increase autocrine and
paracrine signaling (133, 240). However, there is interplay between EGFR
phosphorylation, signaling, and Ca mediated signaling that is not well understood. One
proposed mechanism of Ca/EGFR signaling cross-talk involves a desmosomal cadherin
protein, Dsg1 (128). The desmoglein family of proteins Dsg2 and 3 are expressed in the
stratum basale of the epidermis while Dsg1 is expressed suprabasally (330). Dsg1 is
involved in normal cell adhesion, regulation of cell size, and morphological changes of
differentiating keratinocytes (128) wherein they become broader, flatter, and more tightly
associated with neighboring cells (107). Dsg1 also decreases ERK activity without
affecting total protein content and induces markers of terminal differentiation (K10 and
Lor) in a manner independent of its role in adhesion (128). These data suggest that Ca
regulates keratinocyte differentiation through the inhibition of pro-proliferative ERK
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signaling (173, 236). In addition, they are consistent with the ability of Ca to inhibit EGFmediated induction of ERK signaling in cultured keratinocytes (177) and the reversible
growth arrest and the expression of early markers of differentiation observed in
keratinocytes treated with EGFR inhibitors (236).
In some ways, keratinocyte differentiation is the physiological opposite of
proliferation. However, the reality is more nuanced. Nowhere is this interplay between
differentiation and proliferation more apparent than in epidermal disease. While it is
difficult to parse the hyperinflammatory or autoimmune aspects of chronic skin disorders
such as psoriasis, ichthyoses, or atopic dermatitis, these diseases also contain an
epidermal component wherein the epidermal barrier is compromised, frequently in the
presence of epidermal thickening (142). In these diseases, alteration of keratin expression
or disruption of differentiation-associated lipid synthesis lead to poorly cornified cells
(134, 319). Autoimmune or genetic disruption of desmosomes, TJs, or other cell-cell
contact mimics wounding in an otherwise intact epidermis (120, 153, 331).
As discussed above, the loss of cell-cell contact-dependent juxtacrine connections of
EGFR ligands such as AREG, HB-EGF, and EREG leads to MMP-dependent cleavage of
these ligands (182, 332) and a potential change in how an EGFR ligand signals. For
instance, soluble HB-EGF contributes to wound healing and cellular migration while
membrane-bound HB-EGF maintains a differentiated state and an intact barrier (332).
However, increased amounts of EGFR ligands also drive epidermal proliferation which
leads to epidermal thickening, a trait shared in many chronic epidermal diseases where
EGFR or its ligands are frequently overexpressed in lesional skin (155). Further,
keratinocytes in hyperproliferative skin disorders do not differentiate normally, and
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accelerated migration from basal to suprabasal layers in the presence of mediators of
inflammation leads to thicker plaques of poorly differentiated keratinocytes which further
damage barrier function. In addition, genes associated with keratinocyte differentiation,
such as Lor and Flg, are frequently down-regulated in psoriatic patients (152, 158, 333)
in the presence of upregulated or otherwise heightened presence of EGFR ligands (176) .
Introduction to the Research Questions
NHEK as an in vitro model of epidermal homeostasis
TCDD has historically been studied in cells of various epidermal lineages (Table
6), systems far less complex than multihormone driven systems such as gonads,
reproductive tracts or immune cells, and in vivo endpoints typically involving an
epidermal component (4, 7). In skin, TCDD causes clear and easily interpreted
endpoints in epidermal homeostasis and provides a defined platform for insight into AhR
signaling and epidermal homeostasis. Well-established methods for monolayer and
organotypic cell culture of primary keratinocytes in chemically-defined medium exist in
which to study epidermal proliferation and differentiation (334). These are based upon
initial work by Rheinwald and Green who determined minimal requirements for the
growth and maintenance of primary keratinocytes (334). Further modifications to this
method have led to a defined system wherein primary cell cultures of human
keratinocytes derived from neonatal foreskins establish close intercellular contacts,
stratify, cornify, and express markers of differentiation such as keratins 1 and 10, Ivl,
Lor, Flg, and Tgm1 as in a normal epidermis (334, 335).
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Table 6. Comparisons of keratinocyte cell lines
Cell Line

Source

Transformed

NHEK

Neonatal foreskin

Primary

N/TERT1

Neonatal foreskin

Yes, TERT

Immortal

HaCat

Adult male, distal
periphery of
melanoma
60 yo male, Facial
SCC
85 yo female, SCC

Yes, spont.

Immortal

Yes

Yes, spont.

Immortal

Yes

Yes, spont.

Immortal

Incomplete

SCC-12F
A431

Passages
5

Differentiation Known alterations
Competent?
Yes
Individual genomic
differences
Yes
Loss of p16INK
TERT expression

Abbreviations: TERT –telomerase reverse transcriptase
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Aneuploid
P53 mutation
Enhanced TERT
From immunosuppressed
transplant recipient
P53 deletion
Enhanced EGFR

References
(239, 334)
(339)
(340-342)

(343, 344)
(345)

In vitro, extracellular Ca mimics the gradient existing in vivo where Ca is low
basally and higher in the granular/cornified layers (147, 336). After 24 hours in high
extracellular Ca (between 1.2 and 2.0 mM) more than 95% of keratinocytes are arrested
in G1 phase (337). Differences in physiological and pathophysiological proliferation or
differentiation are not just molecular; marked changes in cellular morphology can be seen
in less than a day (Figure 8). After 20 hours, cells treated with 1.8 mM Ca appear to be
cornifying. They flatten into a larger, more differentiated phenotype and the borders of
cells become less distinct as the NHEKs form a sheet. This morphology has been
correlated with a suprabasal keratinocyte phenotype (13, 338). Conversely cells grown in
the absence of TCDD or Ca, or cells treated with 100 ng/mL recombinant human EGF
maintain clear borders. As time progresses, EGF-treated cells begin to stratify, then take
on a fibroblast-like shape to migrate and fill this new layer. TCDD-treated NHEKs--also
stratify, and take on an irregular appearance marked with vesicles and irregular borders.
However, despite their appearance, TCDD does not induce apoptosis in NHEKs (4) and
later work performed on these cells will show them to be equal if not more responsive to
EGFR ligands than their basal medium-treated cohort. Nevertheless, these cells are
clearly not behaving in fashions comparable to physiological models of proliferation
(EGF) or differentiation (Ca) (4).
TCDD alters proliferation and differentiation
Both TCDD- and Ca-induced differentiation are associated with decreased [125I]EGF binding indicative of EGFR loss from the cell surface (13, 14). However, studies
assessing TCDD and Ca effects on [125I]-EGF binding have not examined the time-course
of receptor loss, compared it to down-regulation produced by EGF, or defined the
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Basal
TCDD

Calcium

EGF

0h

4h

12 h

20 h

48 h

96 h

Figure 8. Confluent NHEKs following treatment with basal medium, EGF,
Ca, or TCDD. EGF and TCDD induce stratification while TCDD and Ca induce
cornification . Final magnification is 40x.
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mechanism by which it occurs. In spite of loss of EGFRs from the cell surface, TCDD
induces the expression of several EGFR ligands including TGF-α and EREG in vivo and
in vitro (3, 7, 9), and promotes a hyperproliferative state in vivo (13, 74, 346). In
keratinocyte cell culture, TCDD increases the secretion and production of several ligands,
including TGF-α in humans and mice and EREG directly through an XRE upstream of
the EREG TSS in mice (7-9). It is not clear that these increases in EGFR ligand secretion
are shown to be directly responsible for alterations in proliferation. Additional data on
TCDD’s role in epidermal proliferation is equivocal and dependent upon growth and
treatment protocols, endpoints, as well as cell lineage (Table 7). In mice, less responsive
hairless (hr-/hr-) mice showed more hyperplasia than TCDD-sensitive mice which
showed accelerated differentiation suggesting TCDD mimics Ca in driving differentiation
and suppressing EGFR signaling (51). However human patients with chloracne present
with epidermal thickening, an effect caused by unchecked proliferation or slowed
epidermal turnover (74).
Although TCDD neither binds to nor directly modifies the EGFR (72), TCDD
may alter cellular proliferation by mimicking some aspects of EGFR signaling (72). Mice
exposed in utero to TCDD or EGF display similar phenotypes including premature eyelid
opening, premature tooth eruption, decreases in body and thymic weight (348), and
abnormal palatogenesis (102). However, TCDD decreases EGFR binding both in vitro
and in vivo (14, 16, 348), a response that was less extensive in murine strains with lower
sensitivity to the effects of TCDD (16). These data correlate TCDD responses with loss
of binding and could result from alteration of EGFR synthesis, phosphorylation status,
transactivation of the EGFR, or through production of an autocrine growth factor
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Table 7. EGFR downregulation leads to differing endpoints depending on treatment condition
Osborne 1986
(16)

Hudson 1985 (14)

Boonstra 1985
(347)

O’Keefe 1983 (15) O’Keefe et al. 1982 (295)

Ca (mM)
low/high

0.05 / 1.1

0.06 / 1.8

0.06 / 1.6

<0.01 / 1.1

0.09 / 1.8

EGF

8 ng/mL

8 ng/mL

10 ng/mL

10 ng/mL

10 ng/mL

TCDD

10 nM

100 nM

--

--

--

Cells

NHEK

SCC-12F

SCC-12F

NHEK

NHEK

Medium

75% DMEM/F12,
penstrep,
hydrocortisone,
ctx, 5% FBS

DMEM

75% D/F, 5% FBS

75% DMEM/F12,
hydrocortisone,
transferrin, ctx

DMEM, hydrocortisone,
transferrin, 5 ng/mL insulin

Pre-binding
treatment

24 h + Ca
0-72 h TCDD

72 h + EGF

--

72 – 144 h EGF

[125I]-EGF
Incubation

30 min, 37oC

24 h + Ca
96 h + TCDD
120 h + EGF
30 min, 37oC

2 h, RT

4 h, 4oC

Preincubation on ice & 30
minutes, 4oC

TCDD ↓ EGFR
Ca ↑ envelope
Ca dependent
5-fold increase in
Differentiated cells do not
binding, 2-fold ↑
competence,
binding loss is
EGFR with no
bind EGF, EGF causes 60%
CE, 51% ↓ DNA
TCDD/Ca behaved
dose-dependent
change in activity
↓ in [125I]-EGF binding at 2
synthesis, 54% ↓ in like Ca rather than
h.
basal cell number
TCDD
Abbreviations: DMEM Dulbecco’s minimal essential medium; F12 –Ham’s F12 medium, FBS-fetal bovine serum, ctx—cholera
toxin, 75% DMEM/F12: 75% DMEM, 25% Ham’s F12
Results

62

(8, 66). One suggested mechanism is that TCDD activates the EGFR in a non-canonical
ligand-independent manner. TCDD increases PKC signaling and thus the activity of
several non-RTKs, resulting in enhanced EGFR phosphorylation in the plasma membrane
(349). For example, the non-RTK, c-src, is bound cytosolically in a complex with Hsp90
and the AhR, and released upon AhR ligand binding (350). When released from the AhR
protein complex by AhR-ligand binding, c-src is activate and could phosphorylate and
activate the EGFR, leading to a ligand-independent TCDD-induced proliferation (211,
351). Alternatively, TCDD-induced production of EGFR ligands could drive TCDD’s
proliferative response through a ligand-dependent receptor activation.
In addition to its proliferative effect, TCDD also accelerates differentiation as
evidenced by assays of barrier function or quantitation of protein or mRNA for markers
of differentiation (1, 5, 18). This occurs in the face of decreases in receptor number,
suggesting that loss of receptor signaling is important, even though TCDD is increasing
ligand production.
Experimental design
Both TCDD- and Ca-treated cells show a loss of [125I]-EGF binding suggesting a
down-regulation or relocalization of EGFRs (15). In NHEKs, exposure to high
extracellular Ca causes concentration-dependent decreases in high affinity [125I]-EGF
binding (15). Likewise, TCDD treatment decreased EGF binding, EGF-induced DNA
synthesis, and increased CE competence (13). Hudson et al. (14) found that this TCDDinduced repression of EGF signaling was enhanced in NHEKs grown in the presence of
high (1.8 mM) extracellular Ca, while binding was less affected in low Ca which selects
for basal, proliferating cells. However, down-regulation is not simply a means of

63

silencing receptor signaling; it can also alter signaling dynamics, serving as another layer
of spatial and temporal control of complex networks of response to environmental cues
(352).
To address how alterations in EGFR signaling modulate the proliferative
capacity of NHEKs, we first explored to what degree EGFR down-regulation leads
to a loss of signaling in Ca-induced keratinocyte differentiation and TCDD-induced
hyperproliferation. In the second chapter of this work we sought to identify which
ligands were produced in NHEKs grown in high Ca (1.8 mM) to define their role in
physiological EGFR down-regulation. We further determined if EGFR down-regulation
affected EGFR competence in activating ERK-signaling, and modified proliferative
capacity. In the third chapter, we explored the impact of TCDD on EGFR downregulation and cellular responses. To answer these questions we used ligand-specific
enzyme-linked immunosorbent assays (ELISAs) to identify and quantify EGFR ligands
secreted under conditions of high Ca or TCDD. We then interfered with ligand activity
and measured the impact on Ca- or TCDD-induced proliferation, ERK activity, or EGFR
down-regulation
While this work addresses the question of how Ca and TCDD induce EGFR
down-regulation, it also shows that even under differentiating conditions, the EGFR still
plays an active role in regulating keratinocyte function. It has also lays the groundwork
for future studies examining the combined role of TCDD and Ca on epidermal
proliferation and differentiation.
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CHAPTER TWO

Calcium causes ligand-independent EGFR down-regulation.

Summary Statement
Ca-induced EGFR down-regulation is EGFR ligand- independent. While TGF-α
and AREG maintain a population of EGFRs which preserve a proliferative capacity in
confluent NHEKs, loss of EGFR ligands is insufficient to reverse EGFR binding loss or
alter signaling through ERK.
Abstract
Extracellular calcium (Ca) induces epidermal differentiation, regulating
desmosome formation and inducing markers of keratinocyte differentiation. Previous
work shows that Ca reduces EGFR by ~50%, suggesting that loss of pro-proliferative
EGFR signals precede differentiation. In this study, we examined the effect of high (1.8
mM) extracellular Ca on [125I]-EGF binding, EGFR ligand secretion, ERK activity, and
proliferation in normal human epidermal keratinocytes. Ca caused a rapid and sustained
decrease in [125I]-EGF binding relative to basal cells. Secretion of the EGFR ligand
amphiregulin (AREG) increased with time in culture, while transforming growth factor-α
(TGF-α) secretion was time- and Ca-dependent. Inhibiting EGFR ligand secretion with
the metalloproteinase inhibitor batimastat reversed EGFR down-regulation in Ca-treated
cells, while neutralizing AREG, TGF-α or both did not. Ca reduced ERK activity in
NHEKs, a response intensified by TGF-α neutralization. However, AREG neutralization
had no effect on this decreased ERK activity. Ca-treated NHEKs had 15% fewer cells
yet EdU labelling showed no significant difference in proliferative capacity.
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Interestingly, the proliferative capacity did depend upon the presence EGFRs. Our data
suggest that Ca-induced EGFR down-regulation is ligand-independent but that
differentiated keratinocytes down-regulate EGFRs but require the continued presence of
EGFRs to maintain a population of proliferating cells.
1. Introduction
Keratinocytes in the stratum basale of the epidermis are cuboidal, undifferentiated
epithelial cells that asymmetrically divide and migrate superficially through the layers of
the epidermis. As they progress upwards, cells undergo cytoskeletal changes that lead to
adopting a squamous phenotype (Arnemann et al., 1993; Franke et al., 1987) and an
increase in tight junctions and desmosomal contacts (Jensen and Proksch, 2009; O'Keefe
et al., 1987). Differentiating keratinocytes undergo changes to their protein expression
profile and the composition of their cellular membrane (Ng et al., 1996; Pillai et al.,
1990), and extrude lamellar granules containing specialized lipids and fatty acids which
contribute to epidermal barrier strength. This process, known as cornification, is integral
in forming the epidermal barrier, which prevents transdermal water loss and infection
(Candi et al., 2005).
Extracellular calcium (Ca) plays an important role in nearly all facets of
epidermal differentiation. Within the epidermis, elevation of extracellular Ca increases
the expression of differentiation markers (Rice and Green, 1979) and causes
redistribution of the desmosomal protein desmoplakin and the formation of desmosomes
(Godsel et al., 2005;O'Keefe et al., 1987). Ca also causes a rapid and sustained downregulation of the epidermal growth factor receptor (EGFR) in a variety of cell lines
(O'Keefe et al., 1982;O 'Keefe and Payne, 1983), suggesting that keratinocyte
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differentiation requires the suppression of the pro-proliferative signaling associated with
EGFR activation. In fact, Getsios et al. (Getsios et al., 2009) showed that the desmosomal
protein desmoglein 1 (Dsg1) suppresses ERK signaling as an important step in promoting
terminal differentiation of confluent keratinocytes. Finally, Ca activates matrix
metalloproteinases (MMPs) which cleave membrane-bound ligands that aid in cell
migration through the epidermis (Edwards et al., 2008; Franzke et al., 2012; Tallant et al.,
2010) as well as transglutaminase 1, which crosslinks proteins in the cellular membrane
to form the stratum corneum (Candi et al., 2005; Thacher and Rice, 1985).
The EGFR is a member of the ErbB family of receptor tyrosine kinases, which
includes the EGFR, ErbB2, ErbB3, and ErbB4 (Prenzel et al., 2001) with EGFR, ErbB2,
and ErbB3 being found in the epidermis (Stoll et al., 2001). The EGFR and its preferred
dimerization partner, ErbB2 (Macdonald-Obermann et al., 2013; Schneider et al.,
2008a;Xian et al., 1997), are found at the highest density in the stratum basale where
keratinocytes are actively proliferating (Jost et al., 2001;Nanney et al., 1990).
Keratinocytes express ErbB3 in suprabasal layers (Kiguchi et al., 2000; Piepkorn et al.,
1994), suggesting that EGFR-ErbB3 dimers are involved in location-dependent
differentiation (De Potter et al., 2001; Macdonald-Obermann et al., 2013; Piepkorn et al.,
2003). Suppression of EGFR signaling is clearly important in promoting differentiation
as, in vitro, treatment of confluent keratinocyte cultures with EGF promotes
transepithelial water loss (TEWL) and down-regulate clusters of genes involved in
ceramide biosynthesis, tight junction formation, and epidermal differentiation (Tran et al.,
2012). In addition, the increased expression of the EGFR and its ligands, which is often
observed in hyperproliferative diseases, is accompanied by impaired barrier function,
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(Schneider et al., 2008b; Segre, 2006). Finally, microarray studies in our lab showed that
EGF treatment upregulates genes involved in epidermal disease (Tran et al., 2012).
Together these data show that EGFR activity plays an important role in determining
keratinocyte differentiation status.
In spite of the importance of the EGFR in cellular proliferation, silencing the
receptor can impede differentiation. EGFR signaling has been linked to activation of
protein kinase C-alpha (PKCα) signaling in differentiating keratinocytes (Koese et al.,
2013;Wallis et al., 2000) and studies in EGFR -/- mice showed hypophosphorylated PKC
impedes post-natal barrier function and causes chronic dermatitis (Denning et al.,
2000;Yang et al., 2003). In fact, murine genetic knockout of TGF-α causes decreased
wound healing (Kim et al., 2001) and abnormal differentiation of hair follicles (Kim et
al., 2001). Further, mice deficient in ADAM17 (an MMP that cleaves pro-EGFR ligands)
do not develop competent epidermal barriers, similar to EGFR -/- mice (Kitajima, 2014).
These data suggest that the EGFR is necessary for complete epidermal differentiation.
Although elevations in extracellular Ca down-regulate EGFRs in keratinocytes,
the mechanism(s) involved is unclear. Typically, receptor down-regulation is ligandmediated and assessed by measuring changes in [125I]-EGF binding. However EGF is not
secreted in the epidermis or its accessory structures. In fact, keratinocytes secrete a
number of EGFR ligands including amphiregulin (AREG), epiregulin (EREG), heparin
binding EGF-like growth factor (HB-EGF), and transforming growth factor-alpha (TGFα) (Macdonald-Obermann et al., 2013;Schneider et al., 2008b). MMP-dependent
autocrine secretion of AREG and TGF-α is important in regulating normal proliferation
and epidermal thickening (Schneider et al., 2008a;Stoll et al., 2010), while HB-EGF
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regulates wound healing and keratinocyte migration (Iwamoto and Mekada, 2000). In
addition, each ligand has a distinct effect on EGFR activation as well as differing abilities
to induce receptor degradation or recycling.
The impact of Ca on EGFR down-regulation, receptor signaling, ligand production,
and proliferation/differentiation have been extensively studied, but using a variety of cell
types, culture conditions and Ca concentrations. (Borowiec et al., 2013). These
differences in culture conditions make it difficult to draw conclusions as to the effects of
Ca on EGFR signaling and responsiveness. Because of the complexity of interpreting
historical data across a wide range of cell lineages and experimental designs, we used a
defined set of culture and experimental conditions to identify the mechanisms of Cainduced differentiation and its impact on EGFR signaling in NHEKs. We show that
elevated extracellular Ca (1.8 mM) rapidly decreases EGFR number and increases the
production of TGF-α. However, despite increases in both AREG and TGF-α downregulation of EGFRs is ligand-independent. In addition, EGFR down-regulation is
associated with decreases in ERK activity and keratinocyte cell number that are not
altered by interfering with AREG or TGF-α availability.
2. Results
EGFR down-regulation by Ca
Previous studies have shown that treating confluent NHEKs with high
extracellular Ca causes the loss of cell-surface EGFRs (Choi et al., 1991;O'Keefe et al.,
1982;Osborne and Greenlee, 1985). In order to determine how rapidly this response
occurs and to compare it to ligand-induced down-regulation by EGF, we performed
radioligand binding assays in NHEKs. EGF (100 ng/ml) rapidly reduced
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Figure 1: Calcium treatment down-regulates EGF receptors. NHEKs were grown
as described in Materials and Methods and treated for the times indicated with EGF
(100 ng/ml) or Ca (1.8 mM) then [125I]-EGF binding was determined as described in
the Materials and Methods. Data have been normalized to protein content and are
expressed as the % time-matched control and reported as the means + s.e.m. of three
experiments assayed in triplicate. The dashed line indicates 100%. * indicates p<0.05
for treatments compared to time-matched control.

101

[125I]-EGF binding to ~10% of control values by 4 h, maintaining this significant
(p<0.05) level of inhibition for the duration of the experiment. Reductions in [125I]-EGF
binding took longer to reach maximal inhibition in Ca-treated cells, with significant
effect on [125I]-EGF binding from 4 hours onward (p<0.05) (Fig. 1). At 8 h, binding was
reduced to 51% of control values and remained between 40-60% through 72 h.
Effect of Ca on EGFR ligand secretion
Keratinocytes secrete several EGFR ligands including AREG, EREG, HB-EGF,
and TGF-α (Macdonald-Obermann et al., 2013; Schneider et al., 2008a). Our observation
that Ca treatment mimics decreased [125I]-EGF binding (Fig. 1) suggested that Ca
induced the secretion of an EGFR ligand(s) that drives EGFR down- regulation. To
assess the impact of Ca on EGFR ligand secretion, we assayed conditioned medium for
the presence of the EGFR ligands TGF-α, AREG, and HB-EGF. These ligands were
chosen based upon literature ties to epidermal disease, wounding, and homeostasis
(Kennedy et al., 2013; Tran et al., 2012). TGF-α secretion was significantly enhanced by
Ca treatment at 72 hours (p<0.05; Fig. 2A) going from 115 pg/ml in basal cells at 72 h to
425 pg/ml. Although AREG secretion increased with time in culture (Fig. 2B), Ca had
no effect on its secretion. HB-EGF concentrations were below the detection limits of our
ELISAs (Appendix A) consistent with the low levels of HB-EGF produced by NHEKs in
culture (Piepkorn et al., 2003).
Role of EGFR ligands in EGFR down-regulation
The data presented in Figure 2 show that NHEKs secrete significantly elevated
levels of AREG at 72 h (p < 0.05) and that TGF-α is elevated in Ca-treated cells (p <
0.05). This suggests that one or both ligands causes the loss of [125I]-EGF binding. To
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Figure 2. Calcium increases TGF-α but not AREG secretion. NHEKs
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three experiments assayed in triplicate. (a) indicates p < 0.05 from Time 0. *
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assess the role of these ligands in mediating Ca-dependent EGFR down-regulation,
NHEKs were treated with Ca in the presence or absence of batimastat, a broad spectrum
metalloproteinase inhibitor (Rasmussen and McCann, 1997). Consistent with observed
decreases in [125I]-EGF binding (Fig. 1), treating NHEKs with Ca significantly reduced
biotinylated EGF binding at 72 h (p<0.05; Fig. 3). Batimastat relieved receptor downregulation in Ca-treated cells such that biotin-EGF binding was not significantly different
from basal cells (Fig. 3A), indicating that that the shedding of a MMP-cleaved protein(s)
relieves EGFR down-regulation. Batimastat was not able to reverse EGF-induced downregulation (Fig. 3A), consistent with EGF addition to the medium rather than being
released by the cells. To identify the ligand involved in EGFR down-regulation, NHEKs
were treated with neutralizing antibodies for AREG or TGF-α alone or in combination.
Surprisingly, neutralizing ligands alone or in combination had no significant effect on
receptor down-regulation suggesting that Ca-induced decreases in biotin-EGF binding
were ligand-independent. (Fig. 3B).
The Effect of Ca on ERK activity
The continued presence of EGFRs and the production of TGF-α and AREG in Catreated cells suggests that cells retain responsiveness to locally produced EGFR ligands.
To determine if this is the case, cells were treated for 72 hours with Ca in the absence or
presence of neutralizing antibodies for AREG (15 µg/ml) or TGF-α (5 µg/ml) alone or in
combination. ERK activity was 55% lower in Ca-treated cells (p<0.05), consistent with
the decrease in EGF binding observed in Figures 1 and 2. However, neutralizing AREG,
TGF-α or both together had no significant effect on ERK activity in basal or

104

A

250

cont

n

( % u n t r e a t e d c o n t r o l)

b io t in E G F B O U N D

bat
200

150

*
100
a
a

a

50

0
basal

B

250

Ca

EGF

cont

( % u n t r e a t e d c o n t r o l)

b io t in E G F B O U N D

a n t i- A R E G
200

a n t i- T G F - 
a n t i- T G F -  + a n t i- A R E G

150

100
a

a
a

50

a

0
basal

Ca

Figure 3. Effect of altering ligand availability on EGFR down-regulation. (A)
NHEKs were treated with Ca (1.8 mM) for 72 h in the absence or presence of batimastat
(bat; 3 µM) or (B) neutralizing antibodies for TGF-α (5 µg/ml) or AREG (15 µg/ml)
alone or in combination. Biotin-EGF binding was then determined as described in
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in the absence of batimastat or neutralizing antibodies. Data are means + s.e.m. of six
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the % biotin-EGF bound in basal cells. (a) indicates significantly different from the
basal control (p <0.05), The dashed line indicates basal control normalized to 100%.
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Ca-treated cells (Fig. 4), indicating that the local production of TGF-α and AREG was
not maintaining ERK activity in these cells.
Role of EGFR ligands in regulating cell number
The continued presence of EGFRs and the production of both TGF- and AREG could
indicate that these ligands play a role in cell proliferation. To assess the effect of
individual EGFR ligands on cell number, we utilized fluorescence-based double stranded
DNA analysis. Treatment with Ca led to a significant 15.2% decrease in cell number
relative to basal cells (Fig. 5A). Neutralizing AREG or TGF-α independently had no
significant effect on cell number in basal or Ca-treated cells. Neutralizing both AREG
and TGF-α significantly reduced cell number in basal cells (p<0.05) but had no greater
effect than Ca alone on cell number in Ca-treated cells (Fig. 5A). To address this EGFRdependence, we measured the impact of interfering with EGFR activity on DNA
synthesis using EdU labeling of actively proliferating cells treated for 72 h with Ca in the
presence or absence of the EGFR inhibitor, PD153035 (300 nM). We first counted the
total number of cells per field and found that it was not significantly different between
basal and Ca- treated cells. PD153035 significantly reduced the number of EdU-labeled
nuclei in basal and Ca-treated cells (Fig. 5B, C) indicating that DNA synthesis is
dependent upon the continued presence of signaling-competent EGFRs.
3. Discussion
The epidermis is a continually renewing stratified epithelium that forms a
protective barrier to the external environment. Proliferating cells in the basal layer
migrate upwards and undergo terminal differentiation to replace cells that are lost to
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Figure 5. Effect of reducing EGFR ligand availability on cell number. In (A)
NHEKs were grown in the presence or absence of neutralizing antibodies for TGFα (5 μg/ml), AREG (15 μg/ml) or both. After treatment, cells were frozen and
dsDNA labeled as described in Materials and Methods. Basal refers to K-SFM
without Ca; vehicle refers to treatments in the absence of neutralizing antibodies.
Data are means + s.e.m. of three separate experiments assayed in tripicate and
reported as percentage of basal vehicle. (a) indicates significantly different from
basal control (p < 0.05). In (B) and (C), NHEKs were grown to confluence in glass
chamber slides and then treated for 72 h with Ca (1.8 mM) in the presence or
absence of PD153035 (300 nM), an EGFR inhibitor. During the last 16 h they were
incubated with 10 mM EdU and labeled as described in the Materials and Methods.
(B) Representative confocal images of total (DAPI; 405 nm, blue) and EdUstaining nuclei (647 nm, pink) at 20x magnification. (C) Proliferative index of Edu
positive nuclei per field (EdU labeled/DAPI labeled). Data are means + s.e.m. from
quantifications of five fields from three separate experiments. ** indicates
significantly different from the within treatment control (< 0.01).
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desquamation. Ca is an important modulator of this differentiation process (Eckert et al.,
2004) with high extracellular Ca rapidly increasing the expression of differentiation
markers such as involucrin, loricrin, and transglutaminase-1 (Rice and Green, 1979) and
more slowly inducing cornification (Pillai et al., 1990). High extracellular Ca also downregulates the EGFR (O'Keefe and Payne, 1983), a response that has been interpreted to
show that differentiation requires suppression of epidermal EGFR signaling (Getsios et
al., 2009; Jensen and Proksch, 2009; O'Keefe et al., 1982; O'Keefe and Payne, 1983).
However, EGFR ligand production (Fig. 2) is maintained in the face of receptor downregulation (Fig. 1) and differentiation (Campion et al., 2016; Rice and Green, 1978)
leading us to wonder what role the ligands play in receptor down-regulation and the
cellular consequences of receptor loss. In this study, we show that the Ca-induced downregulation of EGFRs in NHEK is ligand-independent even though it is associated with
constitutive production of AREG and increased TGF-α secretion. Further, it is associated
with a reduction in ERK activity and cell number but the maintenance of a small pool of
proliferating cells that require the continued presence of the EGFR .
Treatment of NHEKs with high (1.8 mM) extracellular Ca reduced [125I]-EGF
binding by 50% within 8 hours (Fig. 1), a response comparable to that observed by
Osborne and by others (Hudson et al., 1985;Osborne and Greenlee, 1985). ERK activity
decreased to a level comparable to EGFR down-regulation (Fig. 4) and led to a reduction
of total cell number in Ca-treated cells at 72 h (Fig. 5). This would suggest that Cainduced differentiation effectively “turns off” EGFR signaling in order to progress with
epidermal differentiation.
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However, this decrease in receptor number was accompanied by an increase in
TGF-α secretion in Ca-treated cells (Fig. 2B) on a background of elevated AREG at 72 h
(Fig. 2A). Denning et al. (Denning et al., 2000) showed similar effects of Ca on TGF-α
mRNA, indicating that Ca regulates both the expression and production of this EGFR
ligand. In addition, AREG secretion increased with time in culture in both basal and Catreated cells, presenting NHEKs with two EGFR ligands potentially capable of downregulating the EGFR. Additionally, while there were fewer cells in vitro, we found that
EGFR-dependent proliferation in Ca-treated cells was the same as in basal treated cells
(Fig. 5C). These data, conversely, suggest that EGFRs in differentiating keratinocytes are
providing a sufficient proliferative signal in at least a small population of cells, and
provides a mechanism through the release of ligand as to how this may be occurring.
In fact, when basal or Ca-treated cells were treated with the metalloproteinase
inhibitor batimastat, the EGFR down-regulation in Ca-treated cells was reversed (Fig. 4)
and biotin-EGF binding in basal cells was enhanced (Fig. 3A). These data argue that
there is an effect of a locally released ligand(s) on EGFR binding in both basal and Catreated cells. However, when we removed AREG from the culture medium with a
neutralizing antibody, there was no change in biotin-EGF binding in basal or Ca-treated
cells. While interfering with TGF-α appears to intensity EGFR down-regulation in Catreated cells, this change is not significantly different and neutralizing both ligands was
similarly ineffective.
The ability of batimastat to reverse down-regulation while neutralizing antibodies
could not would seem to argue that another EGFR ligand is involved EGFR downregulation. HB-EGF, which down-regulates EGFRs (Stoll et al., 2001), could play this
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role. However, HB-EGF is typically associated with wound healing and keratinocyte
migration (Poumay and de Rouvroit, 2012) responses not activated in our cultures. More
importantly, we could not detect HB-EGF in the medium of basal or Ca-treated cells by
ELISA (Appendix A). Recent studies show that EREG is present in skin and drives
keratinocyte proliferation (Macdonald-Obermann et al., 2013). However, when we
neutralized EREG alone, or in combination with TGF-α and AREG, we could still not
relieve EGFR downregulation (Appendix A). It is possible that a cryptic EGFR ligand
down-regulates EGFRs in the skin, and there is evidence in literature that betacellulin
plays a role in hair follicle development (Schneider et al., 2008b;Shirakata et al., 2010)
and epigen has been shown to play a role in sebaceous gland development and pathology
within the epidermis (Schafer et al., 2014). However, while in vivo, it is possible these
ligands play a role, given their localized expression and secretion, it is less likely that
they are affecting our system which models the interfollicular epidermis.
This leaves two possibilities: First, that batimastat has effects on EGFR levels
independent of EGFR ligand secretion. However, batimastat mimics the MMP cleavage
site in substrate (Brown, 1995) blocking actions of MMPs -1, -2, -3, -7, and 9 (Wang et
al., 2005), and we could find no evidence in the literature for off-target effects on any
signaling molecule that leads to differentiation. This leaves us with the possibility that
EGFR down-regulation is ligand-independent. In fact, Ca activates phospholipase C
independent of a receptor-ligand signaling event (Punnonen et al., 1993). This, in turn,
would result in an increase in protein kinase C (PKC) activity. Since EGFR signaling
activity is inhibited by PKC-dependent phosphorylation of T654 (van Baal et al., 2012)
and PKC activation by phorbol esters reduced EGFR binding by 40-50% in in SV40
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transformed keratinocytes (Xue et al., 1996), PLC-mediated and PKC-dependent signals
might mediate EGFR down-regulation in Ca-treated keratinocytes. Further studies are
required to identify the ligand-independent mechanisms that might result in EGFR downregulation.
Receptor down-regulation is typically thought of as a means of reducing cellular
responses to the continued presence of agonist (Mizuno et al, 2005). If TGF-α and AREG
are not involved in receptor down-regulation, what other role might they play? Recent
studies have shown that receptor down-regulation is an important mechanism for shaping
ERK signaling dynamics and encoding specific cellular responses. In mammary
epithelial cells, autocrine delivery of an EGFR ligand produced a persistent reduction in
EGFR number that promoted cell migration in response to prolonged ERK signaling
(Joslin et al., 2007). In contrast, acute elevations in ERK activity produced by exogenous
EGF were not effective in promoting cell migration. In Ca-treated NHEKs, the reduction
in EGFR binding was accompanied by a marked decrease in ERK activity, a response
comparable to that reported by (Getsios et al., 2009;O'Keefe et al., 1982) and indicating
that having fewer receptors at the cell surface lowered signaling competence.

However,

AREG and TGF-α were not maintaining ERK signaling in basal or Ca-treated cells, as
neutralizing AREG and TGF-α, alone or in combination had no effect on ERK activity.
These data argue that the local production of AREG and TGF-α is not involved in
proliferation, a response typically associated with ERK activity, and we see that this is, in
fact, true for Ca-treated cultures where cell number was significantly lower than that
observed in basal cells and was not affected by neutralizing AREG and TGF-α either
alone or in combination (Fig 5A). In fact, based on the decrease in ERK activity, the
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15% reduction of total cell number in Ca-treated cells at 72 h (Fig. 5) was not unexpected
and suggest that Ca-induced differentiation effectively “turns off” EGFR/ERK signaling
in order to progress with epidermal differentiation. Interestingly, AREG and TGF-α do
appear to be important in maintaining cell number in basal cells, as neutralizing both
ligands significantly lowers cell number. This may not be surprising as the basal cell
medium contains 0.09 mM Ca, a concentration which results in more rapid growth and
greater NHEK saturation densities than that supported by 1.2 mM Ca (Micallef et al.,
2009). Furthermore, EdU labeling of basal and Ca-treated cells indicated that both
populations required a functional EGFR to maintain a pool of proliferating cells (Fig.
5B,C) that was comparable in both cell populations. Removal of EGFR ligands is likely
not affecting cell number in Ca-treated cells as the majority of cells are growth-arrested
and differentiated. In this case, the presence of the small population of proliferating cells
and the maintenance of a reduced number of EGFR at the cell surface might be a
mechanism for preserving EGFR ligand responsiveness in face of damage to the
epithelium. The EGFR-dependent proliferation observed in Fig 5C could be due to transactivation of the EGFR by a Ca-activated non-receptor tyrosine kinase such as pyk2 or
src and there is evidence in literature which shows these proteins are activated during
keratinocyte differentiation (Calautti et al., 2005; Gschwind et al., 2001; Xie et al.,
2005).
Although we did not address this in our study, the last possible role of the ligands in
post-confluent Ca-treated cells is that they play a role in keratinocyte differentiation.
ADAM17-/- mice which do not produce soluble TGF-α show reduced barrier
permeability and delayed differentiation, a phenotype shared by EGFR -/- mice (Franzke
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et al., 2012). This finding is supported by the ability of exogenous TGF-α to rescue
barrier formation (Franzke et al., 2012), and observations that TGF-α mRNA (Denning et
al., 2000) and protein (Fig 2) increase in differentiating cells in vitro. Removal of EGFR
ligands is likely not affecting cell number in Ca-treated cells as the majority of cells are
growth-arrested and differentiated.
Taken together, these data suggest that TGF-α secretion is differentiation-associated
rather than proliferative. In our work, we found neutralizing TGF-α caused noticeable
though non-significant reduction in both biotin-EGF binding (Fig 3B) and ERK
activation (Fig 4). This observation was similar to that in 2,3,7,8-tetrachlorodibenzo-pdioxin (TCDD)-treated NHEKs grown in low (0.09 mM) Ca under identical experimental
conditions (Campion et al., 2016), a condition which causes a differentiation-like
phenotype in proliferative cells. This suggests that TGF-α, rather than driving EGFR
down-regulation and silencing it, is maintaining a basal level of surface-associated
EGFRs capable of responding to EGFR ligand in order to repair and maintain the
epidermis.
In summary, our data show that Ca-induced EGFR down-regulation occurs through
what appears to be a ligand-independent method. Ca induced EGFR down-regulation
while ERK signaling and proliferation require ligands in basal cells. MMP-dependent
secretion of both AREG and TGF-α drives ERK activation and maintains proliferation in
basal keratinocytes. Ca induces TGF-α secretion while AREG production is associated
with increasing time in culture and confluence regardless of treatment. However, while
we show that Ca maintains a small population of EGFR dependent, proliferating cells, the
predominant phenotype induced by Ca is differentiation. It is likely, however, that this
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sub-population of proliferative cells provide a sufficient proliferative capacity to maintain
and repair the epidermis. Further work should be undertaken to examine the extent of this
role of as well as that of secreted EGFR ligands on keratinocyte differentiation.
4. Materials and Methods
Cell Culture
In all experiments, fifth passage NHEKs from neonatal foreskins (Lonza,
Mapleton, IL) were plated at 5,000 cells/cm2 in Costar 24- or 96-well cell culture dishes
(Corning, Corning, NY). Cells were maintained in keratinocyte serum-free medium (KSFM; Gibco Invitrogen, Carlsbad, CA) containing 0.09 mM Ca, 5 ng/ml recombinant
human EGF, and 50 µg/ml bovine pituitary extract (BPE). The medium was changed
every 48 h until confluence. At confluence, cells were changed to K-SFM without
supplements (basal medium) for 48 h then transferred to basal medium containing high
Ca (1.8 mM) as described in each figure legend. In some experiments, EGF (Bachem,
Torrance, CA) was added to basal medium to serve as a positive control for ligandinduced EGFR down-regulation. For immunofluorescence, NHEKs were plated in glass
chamber slides (BD Biosciences, San Jose, CA) that had been coated with fetal bovine
serum. The medium was changed every 72 h until confluence. At confluence, cells were
treated as described above and then subjected to experimental protocols for 72 h.
Binding of labeled EGF to intact cells
Time-dependent loss of cell-surface associated EGFRs was determined in NHEKs
grown to confluence in 24-well dishes (Corning, Corning, NY) and treated for 8-72 h in
Ca-containing medium. Following treatment, cells were washed with HEPES-buffered KSFM. [125I]-EGF/ml (specific activity 1128 Ci/mmol; Perkin Elmer, Waltham, MA) was
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diluted in HEPES-buffered K-SFM with 0.1 % bovine serum albumin (BSA) and binding
reactions were initiated by the addition of 200 µl of [125I]-EGF (250,000 cpm/ml) to each
well in the presence or absence of 1 µg excess unlabeled EGF. Binding reactions were
carried out for 60 min at 37oC and terminated by rapid washing with ice-cold phosphatebuffered saline (PBS). Monolayers were solubilized in 0.2N NaOH and aliquots were
assayed for protein content using a Bio-Rad Protein Assay (Bio-Rad Laboratories,
Hercules, CA), and radioactivity by a Packard Cobra II Gamma counter (Perkin Elmer,
San Jose, CA). Non-specific binding was subtracted from total counts and specific
binding was normalized to protein content. Data are reported as the percentage of
binding observed in time-matched controls and are the means + s.e.m. of three separate
binding experiments assayed in triplicate.
Measurement of AREG, HB-EGF, and TGF-α secretion by NHEKs
NHEK-conditioned medium was collected from basal or Ca-treated cells 4-72 h
after treatment and stored frozen in aliquots at -80oC until analyzed for AREG, HB-EGF,
or TGF-α content using ELISA kits from Abcam (Cambridge, MA). Undiluted samples
were added to the assay and AREG, HB-EGF, and TGF-α content were determined from
standard curves. Data are reported in pg/ml and are the means + s.e.m. of three
experiments assayed in duplicate. HB-EGF was not detected in culture medium from
either basal or Ca-treated NHEKs and was not assessed in the neutralization experiments.
Alteration of ligand activity
To investigate the role of each secreted ligand in the loss of EGF binding, cells
were grown in 96-well cell culture dishes as described above in the presence or absence
of 3 μM batimastat (Tocris Bioscience, Minneapolis, MN) or neutralizing antibodies for
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AREG or TGF-α. To neutralize secreted ligands, antibodies to AREG (15 µg/ml), TGF-α
(5 µg/ml) or both, were added to the medium. Medium was spiked with batimastat or
neutralizing antibody after 36 h of treatment. The effect of interfering with EGFR ligand
availability on cell-surface EGFRs was determined using biotinylated-EGF (Invitrogen,
Carlsbad CA) in a modified protocol from DeWit et al. (, 2000). This assay was adopted
to increase assay throughput and conserve antibody. After treating with Ca + batimastat
or neutralizing antibodies, plates were washed in ice-cold PBS and incubated for 1 h on
ice with 10 ng/ml biotinylated EGF in the presence or absence of 1 µg/ml unlabeled EGF.
Cells were fixed for 30 min at 37oC in 4% formaldehyde, washed once with PBS
followed by two five-minute washes in PBS containing 50 mM glycine. Cells were
blocked in 2% gelatin in PBS with 0.1% Triton X-100 (PBS-T) for 1 h at 37oC, then
incubated for 1 h at 37oC in PBS-T containing 0.2% gelatin and streptavidin-HRP (1:500;
Cell Signaling Technology, Danvers, MA). Plates were subjected to three five-min
washes with PBS-T, and two five-min washes with PBS before developing with 1-Step
Ultra TMB-ELISA Substrate (Thermo Fisher, Waltham, MA). Data were measured
colorimetrically at 450 nm and normalized to crystal violet absorbance at 595 nm (as a
measure of cell number) using a BioTek Synergy H1 microplate reader (Biotek
Instruments, Inc, Winooski VT). Binding was reported as a percentage of that in cells
grown in basal medium without inhibitors or antibodies.
Phosphoantibody Cell Based ELISA (PACE) and crystal violet staining
To test the effects of EGFR down-regulation on basal ERK activity, NHEKs
grown in 96-well plates were treated for 72 h in the absence and presence of batimastat or
EGFR ligand neutralizing antibodies as described above. At 72 h, basal ERK activity
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was measured by PACE assay as described in Kramer et al. (, 2008). Briefly, treatments
were terminated by rapid washing with ice cold PBS and cells were fixed in 4%
formaldehyde in PBS, blocked, and incubated overnight with an activation-specific rabbit
monoclonal antibody [phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204); #4370, Cell
Signaling Technology, Danvers, MA]. The assays were developed by incubating with a
HRP-conjugated goat anti-rabbit IgG and 1-Step Ultra TMB-ELISA Substrate and read at
450 nm. To normalize to cell number, fixed cells were washed and stained with 0.04%
crystal violet (Sigma Aldrich, St. Louis, MO) (w/v) in 4% ethanol. Cells were lysed
overnight in 10% SDS and lysates read at 595 nm following the protocol described by
Kueng et al. (, 1989). Absorbance was read on a BioTek Synergy H1 microplate reader
and data were expressed as a ratio of ERK (450 nm)/cell number (595 nm).
EdU Labeling of NHEKs
Cells grown in glass chamber slides were treated at confluence for 72 h with 1.8
mM Ca in the presence or absence of PD153035, an efficacious and selective EGFR
inhibitor, as described above. Sixteen hours before the end of the experiment, cells were
incubated with 10 μM 5-ethynyl-2´-deoxyuridine (EdU), fixed with 4% formaldehyde in
PBS then permeabilized with 0.5% Triton-X 100 in PBS prior to incubation with the
Click-It reaction cocktail containing copper sulfate (CuSO4) and an AlexaFlourconjugated azide that was crosslinked to cellular EdU as per manufacturer’s protocols
(ClickIt EdU Imaging kit; Invitrogen, Carlsbad, CA). Slides were then coverslipped
using DAPI-containing mounting medium to stain nuclei. Cells were imaged at 20x
magnification on Nikon A1 confocal microscope (Nikon, Inc, Melville, NY) at 647 nm
for EdU-positive nuclei and 405 nm for total nuclei. Identical image capture parameters
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were used for all images. EdU positive nuclei as well as total (DAPI-labeled) nuclei were
counted using CellProfiler version 2.1.0 (Broad Institute, Cambridge, MA). Images were
converted to gray scale then counted via “count objects” selecting for circularity and
filtering using a Mixture of Gaussian (MoG) Global correction with standard threshold
correction factors, and upper and lower bounds (1.0, 0.0, 1.0, respectively) (Carpenter et
al., 2006). Five random fields on each of 3 slides were counted for all treatments and
conditions.
Double-stranded DNA analysis
To support crystal violet data as an indicator of cell number, double stranded
DNA was labelled using the FluoReporter blue fluorometric dsDNA Quantitation kit
(Molecular Probes, Inc, Eugene, OR) following manufacturer’s protocol (362). Briefly,
cells were grown to confluence in black-walled and clear bottom plates and treated with
1.8 mM Ca + 300 nM batimastat or neutralizing antibodies as described above. At 72
hours, medium was removed and plates were frozen at -80oC to lyse cells. Plates were
then thawed and rehydrated with Hoechst 33258 in Tris-NaCl-EDTA buffer and
fluorescence was measured on a BioTek Synergy H1 microplate reader with excitation
and emissions filters at 360 nm and 460 nm, respectively. Cell number in each treatment
group was determined from a standard curve plated at the start of the experiment.
Data analyses
EGFR binding data and PACE assays were performed in three experiments
utilizing triplicate wells. Data were analyzed via two-way ANOVA and significance (p <
0.05) was determined using a Bonferroni post-hoc test as performed in Prism GraphPad
software version 5.0 (La Jolla, CA). TGF-α and AREG ELISAs were performed with
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conditioned medium from three experiments and assayed in duplicate. EGFR ligand
concentration was determined from standard curves and analyzed via one- or two-way
ANOVA with a Bonferroni post-hoc test as appropriate.
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CHAPTER THREE

Role of EGF Receptor ligands in TCDD-induced EGFR down-regulation and
cellular proliferation

Abstract
In cultures of normal human epidermal keratinocytes (NHEKs), 2,3,7,8tetrachlorodibenzo-p-dioxin (TCDD) induces the expression of the epidermal growth
factor receptor ligands transforming growth factor-α (TGF-α) and epiregulin (EREG).
TCDD also down-regulates EGF receptors (EGFR), suggesting that decreases in
signaling contribute to the effects of TCDD. In this study, we treated post-confluent
NHEKs with 10 nM TCDD and assessed its effects on EGFR binding, EGFR ligand
secretion, basal ERK activity, and proliferation. TCDD caused time-dependent deceases
in [125I]-EGF binding to levels 78% of basal cell values at 72 h. Amphiregulin (AREG)
levels increased with time in culture in basal and TCDD-treated cells, while TGF-α and
epiregulin (EREG) secretion were stimulated by TCDD. Inhibiting EGFR ligand release
with the metalloproteinase inhibitor batimastat prevented EGFR down-regulation.
Neutralizing antibodies for AREG and EREG relieved receptor down-regulation while
neutralizing TGF-α intensified EGFR down-regulation. Treating NHEKs with AREG or
TGF-α caused rapid internalization of receptors with TGF-α promoting recycling within
90 min. EREG had limited effects on rapid internalization or recycling. TCDD treatment
increased ERK activity, a response reduced by batimastat and the neutralization of all
three ligands indicating that the EGFR and its ligands maintain ERK activity. All three
EGFR ligands were required for the maintenance of total cell number in basal and
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TCDD-treated cultures. The EGFR inhibitor PD153035 blocked basal and TCDDinduced increases in the number of cells labeled by 5-ethynyl-2´-deoxyuridine EdU),
identifying an EGFR-dependent pool of proliferating cells that is larger in TCDD-treated
cultures. Overall, these data indicate that TCDD-induced EGFR down-regulation in
NHEKs is caused by AREG, TGF-α and EREG, while TGF-α enhances receptor
recycling to maintain a pool of EGFR at the cell surface. These receptors are required for
ERK activity, maintenance of total cell number, and stimulate stimulating the
proliferation of a small subset cells.
1. Introduction
The epidermis is a stratified squamous epithelium that provides a barrier against
the entrance of pathogens and foreign substances and protects the body from dehydration.
Keratinocytes within the stratum basale are cuboidal, undifferentiated epithelial cells that
divide and migrate superficially through the layers of the epidermis. Cells in the stratum
basale maintain the proliferative capacity of the epidermis while the epidermal barrier is
established as cells migrate outwardly and cornify [1]. As they progress upwards and
differentiate, keratinocytes become more squamous-like [2,3], alter their membrane
lipids, cross-link proteins and lose organelles such as mitochondria and nuclei [4-6]. The
differentiation process is accompanied by decreases in epidermal growth factor receptor
(EGFR) number at the cell surface (down-regulation), a reduction in EGFR signaling, and
the attenuation of epidermal proliferative capacity [1,7-9], demonstrating the central role
EGFRs play in the balance between proliferation in the basal layers and differentiation in
the upper layers [10].
Keratinocytes express three members of the ErbB family of receptor tyrosine
kinases, the EGFR (ErbB1), ErbB2, and ErbB3 (reviewed in [11]) with the EGFR
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appearing to be the most important member mediating ligand effects in these cells [12].
The fourth family member, ErbB4, is not expressed in skin [12]. Each ErbB receptor
possesses differing ligand affinities, as well as overlapping, but distinct downstream
signaling cascades and distribution within the epidermis [13]. EGFR activation leads to
receptor dimerization and phosphorylation of tyrosine residues in the receptor’s C
terminus which provides docking sites for scaffolding and signaling molecules. All ErbB
receptors can form homo- or heterodimers but EGFR homodimers engage cellular
endocytic machinery leading to EGFR internalization and degradation, while ErbB
heterodimers recycle to the cell membrane [14,15]. The EGFR is expressed in all
epidermal layers [12], but its density is greatest in the stratum basale where it drives
proliferation in cells that have lost contact with the matrix [16,17].
Cells expressing EGFRs typically produce EGFR ligands that maintain cells in
the absence of exogenous growth factors [18-21]. Normal keratinocytes produce
amphiregulin (AREG), epiregulin (EREG), transforming growth factor-alpha (TGF-α)
and heparin binding EGF-like growth factor (HB-EGF) [11]. Amphiregulin is produced
in the largest quantities, consistent with its ability to induce the strongest autocrine
stimulation to cell growth [22]. In contrast, TGF-α, HB-EGF, and epiregulin are
expressed at very low levels [23]. Keratinocyte production of TGF-α [24,25] and EREG
[26] can also be increased by treating cells with 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD), a response consistent with the ability of TCDD to stimulate proliferation.
However, TCDD-mediated increases in TGF-α and EREG are also accompanied by
accelerated differentiation [27-30] and down-regulation of keratinocyte EGFRs [30-32],
and studies in our lab have shown that inhibiting EGFR activation promotes the
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differentiating effects of TCDD [28]. These data suggest that the loss of EGFR signaling
mediates the accelerated differentiation of TCDD-treated keratinocytes.
Cellular responses to a ligand are determined by the number of receptors
activated, and receptor down-regulation is a mechanism for modifying signaling
dynamics to limit cellular responses [33,34]. The down-regulation of EGFRs observed as
keratinocytes differentiate or in cells treated with TCDD may be an adaptive mechanism
to maintain but redirect responsiveness in the face of continued agonist presence [35]. In
mammary epithelial cells, Joslin et al. [36] showed that local production of EGFR
ligands reduced EGFR number, but elevated basal ERK activity and enhanced cell
migration to levels greater than that produced by exogenous EGF. Thus, rather than
prevent EGFR signaling by receptor down-regulation, the local production of EGFR
ligands by keratinocytes could fine tune EGFR signaling as receptor down-regulation is
inversely proportional to receptor activity [37]. In this study, we used normal human
epidermal keratinocytes (NHEKs) to study the mechanism involved in TCDD-induced
EGFR down-regulation and the impact of down-regulation on EGFR signaling and
cellular proliferation in post-confluent cultures. We show that TCDD increases the
production of TGF-α and EREG, and that down-regulation of EGFRs is mediated by
AREG, EREG, and TGF-α. In addition, we show that TGF-α promotes receptor
recycling. These changes in receptor availability are associated with ligand-dependent
elevations in ERK activity as well as an increase in a small pool of proliferating cells.
2. Materials and methods
2.1. Cell Culture
In all experiments, fifth passage NHEKs from neonatal foreskins (Lonza,
Mapleton, IL) were plated at 5,000 cells/cm2 in Costar 24- or 96-well cell culture dishes
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(Corning, Corning, NY). Cells were maintained in keratinocyte serum-free medium (KSFM; Gibco Invitrogen, Carlsbad, CA) containing 0.09 mM Ca, 5 ng/ml recombinant
human EGF (EGF) and 50 µg/ml bovine pituitary extract. The medium was changed
every 48 h until confluence. At confluence, cells were changed to K-SFM without
supplements (basal medium) for 48 h then transferred to basal medium containing TCDD
(10 nM) as described in each figure legend. In some experiments, recombinant human
EGF (EGF; Bachem, Torrance, CA) was added to basal medium to serve as a positive
control for ligand-induced EGFR down-regulation. For immunofluorescence, NHEKs
were plated in glass chamber slides (BD Biosciences, San Jose, CA) that had been coated
with fetal bovine serum. The medium was changed every 72 h until confluence, at which
time cells were treated for 72 h as described above and then subjected to experimental
protocols as described below.
2.2

EGFR ligand ELISAs
Culture medium was collected from basal and TCDD-treated cells 4-72 h after

treatment and stored frozen in aliquots at -80oC until analyzed for AREG, HB-EGF, or
TGF-α content using ELISA kits from Abcam (Cambridge, MA) and EREG content
using a kit from Antibodies-Online Inc. (Atlanta, GA). Undiluted samples were added to
the assay and ligand content was interpolated from standard curves. Data are reported in
pg/ml and are the means + SEM of three experiments assayed in duplicate.
2.3 Phosphoantibody Cell Based ELISA (PACE) and crystal violet staining
To test the effects of EGFR down-regulation on ERK activity, NHEKs grown in
96-well plates were treated for 72 h in the absence and presence of batimastat or EGFR
ligand neutralizing antibodies as described below. At 72 h, ERK activity was measured
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by PACE assay as described by [38]. Briefly, treatments were terminated by rapid
washing with ice-cold PBS and cells were fixed in 4% formaldehyde in PBS, blocked,
and incubated overnight with an activation-specific rabbit monoclonal ERK antibody
[phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204); Cell Signaling Technology,
Danvers, MA]. The assays were developed by incubating with an HRP-conjugated goat
anti-rabbit IgG and 1-Step Ultra TMB-ELISA substrate and read at 450 nm using a
BioTek Synergy H1 microplate reader. To normalize to cell number, fixed cells were
washed and stained with 0.04% crystal violet (Sigma Aldrich, St. Louis, MO) (w/v) in
4% ethanol following the protocol described in [39]. Cells were lysed overnight in 10%
SDS and absorbance was measured at 595 nm. Data are expressed as a ratio of ERK (450
nm)/cell number (595 nm).
2.4. Interfering with ligand action
To investigate the role of each secreted ligand in EGFR down-regulation, ERK
activation, and TCDD-induced proliferation, cells were grown in 96-well cell culture
dishes in the presence or absence of 3 μM batimastat (Tocris Bioscience, Minneapolis,
MN), a broad spectrum metalloproteinase (MMP) inhibitor [40], or neutralizing
antibodies for TGF-α (5 μg/ml; R&D Systems, Minneapolis, MN), AREG (15 μg/ml;
R&D Systems), or EREG (5 μg/ml; R&D Systems). The neutralizing capability of each
antibody was verified by spiking basal medium with 0-30 ng/ml exogenous TGF-α,
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Fig. 1 Validating the effects of each neutralizing antibody. NHEKs were grown
to confluence as described in the Materials and Methods section then challenged for
five minutes with medium containing the indicated concentrations of exogenous (A)
AREG, (B) EREG, or (C) TGF-α that had been pre-absorbed for 2 h at 37oC with
neutralizing antibody for AREG (15 μg/ml), EREG (5 μg/ml), or TGF-α (5 µg/ml).
ERK activation was then measured as described in the Methods. Data represent
means + SD of triplicate wells from one experiment.

AREG, or EREG and preincubating with or without the appropriate amount of
neutralizing antibody. Plates were then stopped after five minutes, and ERK activation
was measured using a PACE assay. Anti-TGF-α, anti-AREG, and anti-EREG all
effectively neutralized high doses of their respective ligands (Fig. 1). Neutralizing
antibodies were then added to binding assays, PACE assays and proliferation assays as
described.
2.5 [125I]-EGF Binding
Time-dependent loss of cell-surface EGFRs was determined in NHEKs grown to
confluence in 24-well dishes (Corning, Corning, NY) and treated for 4-72 h in TCDDcontaining medium. Following treatment, cells were washed three times with HEPESbuffered K-SFM. [125I]-EGF/ml (specific activity 1128 Ci/mmol; Perkin Elmer,
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Waltham, MA) was diluted in HEPES-buffered K-SFM with 0.1 % bovine serum
albumin (BSA) and binding reactions were initiated by the addition of 200 µL of [125I]EGF (250,000 cpm/ml) to each well in the presence or absence of excess (1 µg/ml)
unlabeled EGF. Binding reactions were carried out for 60 min at 37oC and terminated by
rapid washing with ice-cold phosphate-buffered saline (PBS). Monolayers were
solubilized in 0.2N NaOH and aliquots were assayed for protein content using a Bio-Rad
Protein Assay (Bio-Rad Laboratories, Hercules, CA), and radioactivity by a Packard
Cobra II Gamma counter (Perkin Elmer, San Jose, CA). Specific binding was determined
by subtracting non-specific binding from total counts bound and normalized to protein
content. Data are reported as the percentage of binding observed in time-matched
controls and are means + SEM of three separate binding experiments assayed in
triplicate.
In order to conserve antibody and increase assay throughput while assessing the
role of EGFR ligands in receptor down-regulation, cells were grown in 96-well dishes
treated with EGF or TCDD for 72 h in the presence of batimastat or neutralizing
antibodies as described above. Medium was spiked with batimastat or neutralizing
antibody after 36 h of treatment. The effect of interfering with EGFR ligand availability
on cell-surface EGFRs was determined using biotin-EGF (Invitrogen, Carlsbad CA) in a
modified protocol from de Wit et al. [41]. Plates were washed in ice-cold PBS and
incubated for 1 h on ice with 10 ng/ml biotin-EGF in the presence or absence of 1 µg/ml
unlabeled EGF. Cells were fixed for 30 min at 37oC in 4% formaldehyde, washed once
with PBS, followed by two five-min washes in PBS containing 50 mM glycine. Cells
were blocked in 2% gelatin in PBS with 0.1% Triton X-100 (PBS-T) for 1 h at 37oC, then
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incubated with streptavidin-HRP at a 1:500 dilution (Cell Signaling Technology,
Danvers, MA) in 0.2% gelatin in PBS-T for 1 h at 37oC. Plates were subjected to three
five-min washes with PBS-T and two five-min washes with PBS before developing with
1-Step Ultra TMB-ELISA Substrate (Thermo Fisher, Waltham, MA). Absorbance at 450
nm was read on a BioTek Synergy H1 microplate reader and normalized to crystal violet
absorbance at 595 nm. Data are reported as the percentage of binding in basal cells. To
assess the ability of each ligand to down-regulate EGFRs, post-confluent NHEKs were
exposed to EGF, TGF-α, amphiregulin, or epiregulin for 5-120 min using concentrations
equal to the maximum amount of that ligand in the cultures at 3 days. Cells were then
placed on ice and cell surface receptors were analyzed by measuring biotin-EGF binding
as described above.
2.6

Double-stranded DNA analysis
As our previous study shows that TCDD treatment compromises mitochondrial

function [42], analysis of changes in cell number was measured by double stranded DNA
labeling using the FluoReporter blue fluorometric dsDNA Quantitation kit (Molecular
Probes, Inc, Eugene, OR), following the manufacturer’s instructions. Briefly, cells were
grown to confluence in clear bottom black well plates (Corning Costar, Corning NY) and
treated with 10 nM TCDD in the absence or presence of 3µM batimastat or neutralizing
antibodies. At 72 hours, medium was removed from the cells, and the plates were frozen
at -80oC to lyse cells and release DNA. Plates were then thawed and rehydrated with
Hoechst 33258 in Tris-NaCl-EDTA buffer and fluorescence was measured on a BioTek
Synergy H1 microplate reader with excitation and emissions at 360 and 460 nm,
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respectively. Cell number in each treatment group was determined from a standard curve
plated at the start of the experiment.
2.7 EdU Labeling
At confluence, cells grown in glass chamber slides were treated for 72 h with 10
nM TCDD in the presence or absence 300 nM PD153035 (EMD Millipore, Billerica,
MA), a highly selective EGFR inhibitor. Sixteen hours before the end of the experiment,
cells were incubated with 10 µM 5-ethynyl-2´-deoxyuridine (EdU), fixed with 4%
formaldehyde in PBS then permeabilized with 0.5% Triton-X 100 in PBS. Slides were
incubated with the Click-It reaction cocktail containing copper sulfate and an AlexaFluor
647-conjugated azide that was crosslinked to cellular EdU according to the
manufacturer’s instructions (Invitrogen, Carlsbad, CA). Slides were coverslipped using
DAPI-containing mounting medium to stain nuclei. Cells were imaged at 20x
magnification on a Nikon A1 confocal microscope (Nikon, Inc, Melville, NY) at 647 nm
for EdU-positive nuclei and 405 nm for total nuclei. Identical capture parameters were
used for all images. EdU positive nuclei as well as total (DAPI-labeled) nuclei were
counted using CellProfiler version 2.1.0 (Broad Institute, Cambridge, MA). Images were
converted to gray scale then counted via “count objects” selecting for circularity and
filtering using a Mixture of Gaussian (MoG) Global correction with standard threshold
correction factors, and upper and lower bounds (1.0, 0.0, 1.0, respectively) [43]. The
experiment was performed three times, with three slides per experiment. Five random
fields on each of 3 slides were counted for all treatments and conditions.
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2.8. Data analyses
EGFR binding data and PACE assays were performed in three experiments
utilizing triplicate wells. Data were analyzed via two-way ANOVA and significance (p <
0.05) was determined using a Bonferroni post-hoc test as performed in Prism GraphPad
software version 5.0 (La Jolla, CA). TGF-α, HB-EGF, AREG and EREG ELISAs were

Fig. 2.TCDD decreases [125I]-EGF binding. NHEKs were grown as
described in the Material and methods section and (A) treated for the times
indicated with EGF (100 ng/ml) or TCDD (10 nM), then [125I]-EGF binding
was determined. Data are reported as the means + SEM of three experiments
assayed in triplicate. * indicates p<0.05 for treatment effect compared to timematched control (B) NHEKs were treated for the times indicated with
increasing concentrations of EGF (0.1-100 ng/ml), then [125I]-EGF binding
was determined. Data means + SD of one experiment assayed in triplicate.
The dashed line in (A) and (B) indicates 100%.

performed with culture medium collected from three experiments and assayed in
duplicate. EGFR ligand concentrations were determined from standard curves and
analyzed via one- or two-way ANOVA with a Bonferroni post-hoc test, as appropriate.
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3. Results
3.1. EGFR down-regulation in TCDD-treated cells
Previous studies have shown that treating NHEKs for 1-4 days with TCDD causes
the loss of cell-surface EGFRs (30-32). To determine how rapidly this response occurs and
to compare it to ligand-induced down-regulation by EGF, we performed radioligand
binding assays in NHEKs. EGF (100 ng/ml) rapidly reduced [125I]-EGF binding to
roughly 10% of control values by 4 h, maintaining this significant (p<0.05) level of
inhibition for the duration of the experiment (Fig. 2A). In contrast, TCDD treatment had
a limited effect on [125I]-EGF binding during the first 24 h but by 48 h, binding had
decreased to 64% of control. At 72 h, binding rebounded to 78% of control values, but
was still significantly lower than that in time-matched cells. In no case was the reduction
in binding in TCDD-treated cells as rapid or as complete as that observed with EGF
treatment. The decrease in [125I]-EGF binding observed in EGF- or TCDD-treated cells
was not the result of time-dependent decreases in basal cell receptor number, as binding
did not change significantly with time in culture (Fig. 3).
To determine if lower doses of EGF could mimic the levels of down-regulation
observed in TCDD-treated cells, NHEKs were treated with EGF (0.1-100 ng/ml)
followed by the measurement of [125I]-EGF binding. In cells treated with 0.1 ng/ml EGF,
[125I]-EGF binding was reduced to 90% of control within 24 h while 1 ng/ml EGF
reduced binding to 60% of control within 12 h. By 72 h, [125I]-EGF binding had returned
to control levels in cells treated with either EGF concentration. Increasing the EGF dose
to 10 or 100 ng/ml produced a more rapid, extensive, and persistent reduction in [125I]EGF binding, reaching ~40% of control levels by 72 h for 10 ng/ml and 12% of control
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values for 100 ng/ml (Fig. 2B). These data show that the degree of receptor loss is dose-
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Fig 3. Changes in [125I]-EGF binding with time in culture. Basal NHEKs
were grown as described in the Materials and Methods section and total
[125I]-EGF binding was determined at each time point. Data are normalized
to and reported as a % of total binding at T0 and reflect the means + SEM of
three experiments assayed in triplicate.

3.2. Effect of TCDD on EGFR ligand secretion
Keratinocytes secrete several EGFR ligands including AREG, EREG, HB-EGF,
and TGF-α (see Pastore et al. [11]) with TCDD reported to increase the expression and
production of TGF-α [24,25], and AREG [44]. Our observation that TCDD treatment
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decreases [125I]-EGF binding (Fig. 1) suggested that the local production of an EGFR
ligand(s) may drive receptor down-regulation. To assess the impact of TCDD on EGFR
ligand secretion, we measured AREG, EREG, TGF-α, and HB-EGF in culture medium
over the course of 72 hours. These ligands were chosen based upon literature, ties to
epidermal disease and homeostasis, and evidence of TCDD-induced changes in mRNA
expression by RT-PCR or microarray [42]. AREG secretion increased with time in
culture. was comparable in both basal and TCDD-treated cells, and was inhibited by the
broad-spectrum MMP inhibitor batimastat (Fig. 4A,D). EREG secretion was minimal
(26 pg/ml) in basal cells, but at 72 h was present at a concentration of 718 pg/ml in
culture medium from TCDD-treated cells (Fig. 4B). Like AREG, EREG production was
inhibited by batimastat (Fig. 4E). Batimastat-sensitive TGF-α secretion by basal cells
increased by 65 % at 72 hours and TCDD significantly enhanced TGF-α production over
basal cells at 72 hours treatment (Fig. 4C, F), a response comparable to that reported by
Choi et al. [24]. At 72 h, the concentration of TGF-α in the medium from basal cells was
119 pg/ml, versus 428 pg/ml in TCDD-treated cells. This value is comparable on a molar
level to ~ 0.5 ng/ml EGF, a value between the low doses of EGF (0.1 and 1 ng/ml) that
produce modest decreases in [125I]-EGF binding in Fig. 1B. HB-EGF concentrations
were below the detection limits of our ELISA (data not shown), consistent with the low
levels of HB-EGF produced by NHEKs in culture [45] and its primary role in wound
healing and keratinocyte migration [46]. Together, the data in Fig. 4 indicate TCDD
modifies both the ligands produced and the concentrations available to the cells.
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Fig. 4. Effect of TCDD on MMP-dependent EGFR ligand secretion. NHEKs
were treated for 2-72 h with TCDD (10 nM) and the culture medium was collected
for the measurement of EGFR ligands. (A) AREG, (B) EREG or (C) TGF-α content
were determined by ELISA as described in Materials and methods section. Data are
means + SEM of three experiments assayed in duplicate. * indicates significantly
different from time-matched control (TMC), p< 0.05. In D-F, cells were treated for
72 h with vehicle or TCDD + 3 µM batimastat (bat). The culture medium was
collected at 72 h for the measurement of (D) AREG, (E) EREG, or (F) TGF-α. ND
indicates not detectable.
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3.3 Role of EGFR ligands in EGFR down-regulation
The data presented in Fig. 4 show that NHEKs secrete AREG, EREG, and TGFα, with TCDD enhancing the production of EREG and TGF-α. These data suggest that
an EGFR ligand(s) causes the loss of [125I]-EGF binding observed in TCDD-treated cells.
To examine the role of these ligands in mediating TCDD-dependent EGFR downregulation, NHEKs were treated with TCDD or EGF in the presence or absence of
batimastat (3 µM) or neutralizing antibodies for AREG, EREG, or TGF-α, alone or in
combination. Consistent with [125I]-EGF binding (Fig. 2A), 10 nM TCDD and 10 ng/ml
EGF significantly reduced biotin-EGF binding at 72 h with TCDD decreasing binding to
44+11% and EGF to 38+19% of basal cells (Fig. 5A). Batimastat relieved receptor
down-regulation in TCDD-treated cells, indicating that the release of soluble EGFR
ligands was driving receptor loss from the cell surface. As expected, batimastat had no
effect on receptor down-regulation produced by the addition of exogenous EGF.
To examine the individual roles of the EGFR ligands in receptor down-regulation,
NHEKs were treated with neutralizing antibodies for AREG, EREG, or TGF-α. TCDD
treatment reduced biotin-EGF binding to 43 + 7% of basal control values (Fig. 5B), and
neutralizing AREG or EREG returned binding to levels that were not significantly
different from basal control cells (67 + 13% and 61 + 10% of basal control levels,
respectively). These data indicate that both AREG and EREG contribute to EGFR downregulation in TCDD-treated cells. In contrast, neutralizing TGF-α in TCDD-treated cells
significantly enhanced EGFR down-regulation (11 + 1% of basal control levels),
suggesting that TGF-α promotes receptor recycling rather than down-regulation. When
TCDD-treated cells were incubated with all three neutralizing antibodies, biotin-EGF
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Fig. 5. Reducing EGFR ligand availability modifies EGFR downregulation in response to TCDD. (A) NHEKs were treated with or without
TCDD (10 nM) or EGF (10 ng/ml) for 72 h in the absence or presence of
batimastat (bat; 3 µM) or (B) neutralizing antibodies for AREG (15 µg/ml),
EREG (5 µg/ml), TGF-α (5 µg/ml), or all three growth factors (anti-all-GF)
for 72 h. The measurement of biotin-EGF binding was then determined as
described in the Material and methods section. Basal refers to medium (KSFM) without TCDD; control refers to treatments in the absence of
batimastat or neutralizing antibodies. Data are means + SEM of six
experiments assayed in triplicate, normalized to crystal violet staining, and
reported as the % biotin-EGF bound in basal control cells. (a) indicates
significantly different from the basal control at p < 0.05. * indicates
significantly different from the within treatment control (p <0.05).
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binding remained at levels about 30 % of basal, indicating that the effect of neutralizing
TGF-α predominates at 72 hours post-confluence.
The enhanced down-regulation of EGFRs when TGF-α was neutralized suggested
that TGF-α may alter EGFR trafficking in TCDD-treated cells. Since the fate of an
internalized receptor has a substantial impact on the duration of a receptor signal [36,47],
we examined the effect of pretreating NHEKs with EGF, AREG, EREG or TGF-α on
biotin-EGF binding. NHEKs were treated for 5-120 min with concentrations of
exogenous EGFR ligands comparable to the levels found in conditioned medium at 72 h,
then the amount of biotin-EGF binding was assessed. As observed in Fig. 2, treatment
with EGF caused a rapid reduction in biotin-EGF binding to 11 + 4% of T0 values, a
response that was sustained throughout the experiment (Fig. 6). TGF-α reduced binding
to 87% of T0 values within 10 min, while AREG reduced binding to 63% of T0 values by
15 min. EREG did not affect biotin-EGF binding at any time point. These data are
consistent with all three ligands producing effects on EGFR trafficking distinct from
those of EGF, and suggest that one or all maintain a population of EGFRs at the cell
surface.
3.4. Effect of EGFR ligands on ERK activity
Human keratinocytes maintain high steady-state levels of ERK activity due to the
autocrine production of EGFR ligands [48] and the continued presence of EGFRs (Fig
5B) could be important in maintaining ERK activity. In fact, ERK activity was elevated
in TCDD-treated cells as early as 24 h after the start of the treatment even in the face of a
reduction in the number of EGFRs, and was significantly greater than time-matched
controls at 72 h (Fig. 7A). To determine which EGFR ligand(s) enhanced ERK activity,
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Fig. 6. EGFR ligands differentially alter EGFR recycling. NHEKs were
treated for 0-120 min with 60 ng/ml EGF and concentrations of ligands
present in culture medium at 72 h (3000 ng/ml AREG, 412 ng/ml TGF-α or
627 ng/ml EREG) then biotin-EGF binding was measured on ice to prevent
internalization. The amount of biotin-EGF bound was then determined as
described in the Materials and methods section. Data are means + SEM of
triplicate experiments. (a) indicates significantly different from T0 (p < 0.05).
The dashed line represents biotin-EGF binding at T0.

we treated cells for 72 h with TCDD in the absence or presence of batimastat (3 µM) or
neutralizing antibodies for AREG, EREG, or TGF-α alone, or in combination.
Batimastat reduced ERK activity to 52% and 55% of control levels in both basal and
TCDD-treated cells, respectively (Fig. 7B). These data indicate that the residual EGFRs
present on the cell surface are sufficient to maintain EGFR-dependent ERK activity in
response to locally secreted EGFR ligands in both basal and TCDD- treated cells. When
we examined the roles of each EGFR ligand in maintaining ERK activity, neutralizing an
individual ligand had no impact on the elevated ERK activity observed in TCDD-treated
cells. However, when NHEKs were incubated with all three neutralizing antibodies,
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Fig. 7. TCDD-mediated increases in ERK activity are EGFR ligand-dependent. To
assess the effect of TCDD on basal ERK activity over 72 h, NHEKs were grown for 0-72
h with or without 10 nM TCDD and (A) basal ERK activity was measured at the indicated
times as described in the Materials and methods section. Data are reported as % time
matched control and are means + SEM of three experiments assayed in triplicate. *
indicates significant difference from the time-matched control (p < 0.05) (B) To assess
the role of secreted ligands on ERK activity, NHEKs were treated for 72 h with TCDD in
the presence or absence of batimastat (bat; 3 M) or (C) neutralizing antibodies for
AREG (15 µg/ml), EREG (5 µg/ml), TGF-α (5 µg/ml), or all three growth factors (antiall-GF). Basal refers to medium (K-SFM) without TCDD; control refers to treatments in
the absence of inhibitors. Data are means + SEM of three experiments assayed in
triplicate. In B, C, * indicates significantly different from TCDD alone (p < 0.05) and (a)
indicates significantly different from basal control (p < 0.05). The dashed line indicates
the basal control normalized to 100%.
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ERK activity was reduced to levels that were not significantly different from untreated
basal cells (Fig. 7C). These data indicate that all three ligands are required to produce
the increase in ERK activity observed in TCDD-treated cells.
3.5. Role of EGFR ligands in regulating cell number
The presence of AREG, EREG, and TGF-α in NHEK culture medium and the
observation that all three ligands have an effect on EGFR down-regulation as well as
maintenance of ERK activity led us to examine the role of each ligand plays in the
proliferative response reported in TCDD-treated cells [25,26,49]. Cell numbers at 72
hours were not different in basal and TCDD-treated cells (95713 + 2251 vs 94,360 +
3175, respectively; Fig. 8A). These results are not surprising as these are post-confluent
cultures. Neutralizing each individual ligand produced modest reductions in cell number,
with greatest effect occurring in basal and TCDD-treated cells treated with the AREG
antibody (a 6 % drop from 95,714 + 2251 to 90,314 + 650 cells in basal cultures and a 7
% drop from 94,380 + 3175 to 88027 + 1412 cells in TCDD-treated cultures). While the
loss of individual ligands was not statistically significant, neutralizing all three ligands
reduced cell number significantly in both basal (10.3%) and TCDD-treated (11.3%) cells.
These data indicate that all three EGFR ligands play a role in maintaining cell number in
post-confluent monolayers of basal and TCDD-treated cells.
Since TCDD produced no significant increase in cell number compared to basal
cells, we wondered whether there might be a small population of cells proliferating in
response to TCDD. To address this question, we measured DNA synthesis using EdU
labeling in cells treated for 72 h with TCDD in the presence or absence of the EGFR
inhibitor PD153035 (300 nM). Compared to basal cells, TCDD treatment significantly
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Fig. 8. Reducing ligand availability affects cell number and
proliferation. (A) NHEKs were grown in the presence or absence of
neutralizing antibodies for AREG (15 µg/ml), EREG (5 µg/ml), TGF-α (5
µg/ml) or all three growth factors (anti-all-GF) antibodies. After treatment
cell number was measured as described in the Materials and methods
section. Basal refers to medium (K-SFM) without TCDD; control refers to
treatments in the absence of neutralizing antibodies. Data are means + SEM
of three separate experiments assayed in triplicate. * indicates significantly
different from within treatment control. (B) and (C), NHEKs were grown to
confluence in glass chamber slides and then treated for 72 h with TCDD (10
nM) in the presence or absence of PD153035 (300 nM), an EGFR inhibitor.
During the last 16 h cells were incubated with 10 µM EdU to label
proliferating cells. (B) Representative confocal images of total (DAPI; blue)
and EdU-staining nuclei (pink) at 20x magnification. Basal refers to
medium (K-SFM) without TCDD; control refers to treatments in the absence
of PD153035. (C) Proliferative index is determined as the percentage of the
total cell population labeled by EdU [(EdU labeled/DAPI labeled) x100].
Data are means + SEM from counting five fields from three separate
experiments. * indicates significantly different from the within treatment
control (p< 0.05). (a) indicates significantly different from basal control
(p<0.05).
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increased the percentage of the cell population that was proliferating (Fig. 8B,C).
Inhibiting EGFR activity with PD153035 significantly reduced this percentage in both
basal and TCDD-treated cells. The increased percentage of EdU positive nuclei in
TCDD-treated cells in the face of a total cell population comparable to that of basal
cultures, suggests that TCDD-treated cultures have a larger proliferative capacity than
basal cells even in these post-confluent cultures.
4. Discussion
The epidermis regenerates constantly, requiring the concurrent expression of
proliferative programming in the basal layer and differentiation programming in the
suprabasal layers [16,17]. The EGFR and its ligands play critical roles in regulating the
balance between proliferation and differentiation. EGFR number is greatest in the basal
layer of the epidermis where its activation promotes proliferation and declines as
keratinocytes migrate suprabasally and undergo terminal differentiation [16,17]. The
EGFR and its ligands establish an autocrine loop in the skin with receptor activation
stimulating cell proliferation in the basal layer, and with decreases in EGFR levels as the
cells migrate suprabasally and differentiate [11,16,17]. The environmental toxin TCDD
alters this autocrine loop by promoting EGFR down-regulation [30-32] and enhancing the
production of receptor ligands [24-26]. These apparently opposing responses have been
used to explain the proliferative effects of TCDD (increased EGFR ligand production)
and its ability to accelerate keratinocyte differentiation (EGFR down-regulation and loss
of signaling). However, in vitro studies have shown that the increase in ligand
production occurs in the face of reduced receptor number, an effect that should alter the
cells’ ability to respond to the ligands. Since cellular responses to an agonist reflect the
number of receptors activated [37], we were interested in understanding how a decrease
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in receptor number accompanied by increased ligand production might mediate the
effects of TCDD in NHEKs. Using post-confluent NHEKs, we show that TCDD
increases the production of TGF-α and EREG, and that down-regulation of EGFRs is
mediated by AREG, EREG and TGF-α. In addition, we show that TGF-α promotes
receptor recycling. These changes in receptor availability are associated with an increase
in steady-state ERK activity that is ligand-dependent, as well as an increase in a small
pool of proliferating cells which maintains total cell number.
Basal NHEKs increase their AREG production while producing only small
amounts TGF-α and virtually no EREG. Since basal cells are grown in the absence of
added growth factors, these data indicate that AREG is the EGFR ligand maintaining
these cells in the absence of exogenous growth factors [18-21]. These data are consistent
with the observations of Piepkorn et al. [22] who showed that AREG is the most
abundant and efficacious regulator of keratinocyte growth. TCDD-treated keratinocytes
produced comparable amounts of AREG but had elevated production of both TGF-α and
EREG, responses also observed by Choi et al. [24] and Patel et al. [26]. These changes
in all three ligands occur at the same time that receptor numbers are declining, arguing
that one or more of these ligands mediates EGFR down-regulation in TCDD-treated cells.
When we inhibited EGFR ligand release with the MMP inhibitor batimastat, receptor
binding increased not only in TCDD-treated cells but also in basal cells, arguing that a
ligand(s) is modulating the number of cell surface receptors in both cell populations.
Subsequent experiments with ligand-neutralizing antibodies showed that the elimination
of all three ligands reduced receptor number in both basal and TCDD-treated cells. This
was somewhat surprising as we expected the removal of all the ligands to relieve receptor
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down-regulation. In fact, neutralizing either AREG or EREG in TCDD-treated cells
partially restored biotin-EGF binding; however eliminating TGF-α intensified receptor
loss, a response also observed in basal cells. Although AREG predominates in basal
cells, at 72 hours, TGF-α is elevated in basal cells and markedly enhanced in TCDDtreated cells, suggesting that TGF-α may maintain a pool of EGFRs at the cell surface in
both basal and TCDD-treated cells. This would be consistent with the ability of TGF-α
to bias EGFRs to the cell membrane [47,50]. In fact, our observation that exogenous
TGF-α increases EGFR binding at the cell surface supports this role of TGF-α, although
these data must be interpreted cautiously as exogenous addition of ligands does not
reflect the impacts of autocrine secretion of EGFR ligands [36]. TGF-α-induced
increases in cell membrane-associated EGFRs has also been observed in prostate cancer
cells where the ligand stabilizes EGFR mRNA and enhances the de novo synthesis of the
receptor [51]. Vassar and Fuchs [52] showed that there were no major differences in
EGFR levels in TGF-α-overexpressing mice compared to normal, demonstrating that
TGF-α does not promote the loss of EGFRs. Together these results demonstrate that the
combined effects of the three ligands is to maintain a reduced number of receptors on the
cell surface by causing down-regulation (AREG, EREG, and TGF-α and promoting
recycling (TGF-α).
Receptor down-regulation is typically thought of as a way to for cells to modify
their responses to continued agonist presence. Differences in signaling dynamics (signal
intensity, frequency, and duration) can encode specific cellular responses [34], as
exemplified by studies from Joslin et al., [36] who showed that the autocrine production
of EGFR ligands leads to a persistent reduction in EGFR number but a sustained
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elevation in ERK activity that mediated an enhanced migratory response compared to that
produced by exogenous EGF. Likewise, we show that the TCDD-induced downregulation of EGFRs in NHEKs was accompanied by an elevation in ERK activity that
was significantly greater than that in basal cells and maintained by the autocrine
production of AREG, EREG, and TGF-α. The production of EGFR ligands also
maintained ERK activity in basal cells, consistent with the findings of Iordanov et al..
[48]. In addition, these data indicate that TCDD alters an autocrine loop already present
in keratinocytes by reducing receptor number with AREG, EREG, and TGF-α and
maintaining cellular responsiveness to secreted ligands by TGF-α-induced receptor
recycling.
Increases in ERK activity mediate a host of cellular responses including
proliferation [53]. Both basal and TCDD-treated cells grow in the absence of exogenous
growth factors, reflecting the ability of locally produced EGFR ligands to activate ERK
and maintain total cell number. However, the total number of cells in basal- and TCDDtreated cultures were not significantly different. This result was not surprising as our
monolayer cultures are post-confluent and more reflective of intact skin. Neutralizing
individual ligands had modest impacts on cell number in basal or TCDD-treated cells, but
in both basal and TCDD-treated cells the response was greatest in cells treated with
AREG antibodies, consistent with AREG being the most abundant and efficacious
regulator of keratinocyte growth [22]. Cell number was significantly reduced in basal
and TCDD-treated cells when all three ligands were neutralized. Since NHEKs stratify in
this culture system, our data suggest that the EGFR ligands are required for the
homeostatic replacement of cells lost to sloughing during the culture period in both basal
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and TCDD-treated cells. However, the complement and concentrations of EGFR ligands
produced by basal and TCDD-treated cells was different, with TCDD causing a much
larger increase in TGF-α production than observed in basal cells and stimulating the
production of EREG. Since hyperproliferation is a well-described response to TCDD in
vitro [25,26,49] and in vivo [44], we asked whether or not the TCDD could enhance the
number of proliferating cells in the culture. EdU labeling of basal and TCDD-treated
cells indicated that both populations required a functional EGFR to maintain a small pool
of proliferating cells. In addition, TCDD-treated cells, which have a higher concentration
of secreted TGF-α compared to control cells and produce EREG, show a greater
percentage of EdU positive cells, indicating that these cultures have a greater
proliferative capacity. These data support the idea that the hyperproliferative effect of
TCDD in NHEKs is the result of producing a larger population of proliferative cells
within a differentiating epidermis. Maintenance of this proliferative pool in basal cells
reflects the ability of AREG to promote proliferation while the small amounts of TGF-α
produce by these cells maintains receptor number and ligand responsiveness. AREG and
TGF-α would serve the same purpose in TCDD-treated cells, but the enhanced
production of TGF-α and EREG is responsible for the increased size of the proliferative
pool of cells in these cultures.
In summary, our data indicate that TCDD alters an autocrine loop present in
keratinocytes by enhancing the production of EGFR ligands and modifying EGFR
trafficking to maintain the cells’ responsiveness to locally produced growth factors. The
alteration in EGFR number in TCDD-treated cells required AREG, EREG, and TGF-α
and is accompanied by a TGF-α-mediated recycling of receptors that maintains a pool of
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Fig. 9. TCDD alters the EGFR/ligand autocrine loop present in
keratinocytes. (A). TCDD-induced EGFR internalization in NHEKs
reflects the combined effects of AREG, EREG and TGF-α, while TGF-α
promotes EGFR recycling. This receptor pool preserves the cell’s ability to
respond to the local production of AREG, EREG, and TGF-α leading to a
sustained elevation in ERK activity compared to basal cells. (B) The
enhanced production of TGF-α and EREG enhances the proliferation of a
small subset cells in the basal or suprabasal layers of the skin that serve to
maintain total cell number.
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receptors at the cell surface. This receptor pool preserves the cell’s ability to respond to
the local effects of AREG, EREG, and TGF-α leading to a sustained elevation in basal
ERK activity and the maintenance of a pool of proliferating cells that can quickly respond
to disruption of the culture and replace cells lost to sloughing of the stratifying culture
(Fig. 9).
5. Conclusion
TCDD treatment of NHEKs produces a ligand-dependent decrease in EGFR
number that is limited by the ability of TGF-α to promote receptor recycling. These
ligands and receptor changes enhance the activity of the autocrine loop that sustains the
monolayer with TGF-α promoting EGFR recycling and upregulation as well as sustained
levels of ERK activity that promote homeostatic replacement of cells during the culture
period.
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CHAPTER FOUR

Conclusions and recommendations for future work
Concluding remarks
The role of EGFR in keratinocyte differentiation becomes increasingly complex
as our understanding of receptor signaling dynamics and down-regulation evolves. But
this work is not the first that argues EGFR plays a role in physiological or
pathophysiological keratinocyte differentiation. Previous studies have shown that Cainduced inactivation of EGFR signaling is a result of PKC-dependent receptor
phosphorylation (1)—a process in which activated EGFR create a negative feedback loop
which leads to EGFR silencing (1) and is observed in migrating and differentiating
keratinocytes both in vitro and in the upper layers of the epidermis in vivo (2, 3).
TCDD similarly produces EGFR down-regulation and its signaling, a response
which is correlated with keratinocyte differentiation. TCDD induces processes typically
associated with keratinocyte differentiation, such as accelerated expression of markers o
differentiation and lipid biosythetic genes in the epidermal differentiation complex (4-6)
as well as increased functional markers of differentiation such as increases in percentage
of cornified envelopes in vitro (4, 5, 7) and acceleration of epidermal barrier formation in
utero (8, 9). These TCDD-induced phenotypes have been shown to be both inhibited by
EGF and dependent upon the AhR (5, 6, 8). However, TCDD is also considered to be
pro-proliferative, though these claims are more subject to experimental conditions
endpoints (7, 10, 11) or suggest that TCDD functions in a proliferative capacity on subset
of keratinocyte populations (12). However, the ability of TCDD to induce proliferation is
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influenced by multivariate experimental cell culture conditions, timepoints, and cell
lineages which complicate cross-study comparison which might otherwise suggest a
mechanism.
While TCDD and Ca both induce keratinocyte differentiation, the nature of the
changes in gene expression and barrier function are distinct. In this study, we address the
ambiguity by examining Ca and TCDD effects in a single type of keratinocyte utilizing
the same timepoints and downstream targets for EGFR regulation. What is perhaps most
novel about this work is that, by bringing together and expanding upon experiments
performed over the years in differing cell lines, culture conditions, and over varying time
courses (Table 1.7), we are able to directly compare how Ca and TCDD-treatment alter
EGFR signaling relative to one another and provide insight into mechanistic differences
in between the two that can be applied to future work investigating TCDD-treatment in
high Ca.
Loss of surface associated [125I]-EGF binding observed in Ca- and TCDD-treated
cells and the extent of this down-regulation differed. More importantly, the ability to
reverse downregulation differed by treatment. In our work, Ca-treated cells still had 41%
of the surface-associated EGFRs observed in basal cells (Figure 2.1), a number similar to
observations in literature (13, 14), and this appears to be sufficient for EGFR-dependent
barrier formation and wounding response. However, TCDD-treated cells maintained 78%
of surface associated EGFRs suggesting a much less pervasive down-regulation (Figure
3.2). In both cases, the loss of EGFR was accompanied by elevated levels of EGFR
ligands though the complement of secreted ligands differed. Denning et al. showed that
Ca increased TGF-α mRNA nearly 30-fold--though did not look at protein (1). Our work
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expands on this to show that TGF-α protein increased following not only treatment with
high Ca (Figure 2.2) , but also TCDD in low Ca conditions (Figure 3.4) which had been
suggested though not directly shown in keratinocytes (15, 16). In this work, Choi et al.
(16) identified TGF-α in keratinocyte-conditioned medium but tested EGFR downregulation through the use of EGF. Additionally, explaining this down-regulation of
EGFR as entirely TGF-α-dependent fails to recognize the contribution of other EGFR
ligands: AREG and EREG which were not investigated (or in EREG’s case, known) at
the time. We found that TCDD-treated cells secreted elevated levels of EREG (Figure
3.4) while AREG secretion increased in all cells, including basal cells over time in
culture. While the presence of secreted ligand in basal cells provides a clear mechanism
of EGFR activation, in differentiating cells, ligand secretion creates a seemingly
paradoxical environment where surface associated EGFR is reduced in the presence of
elevated receptor ligands.
This offers some insight into mechanisms of epidermal plasticity. Even within the
differentiated, intact epidermis, an extracellular environment rich in proliferative ligands
facilitates epidermal migration and re-epithelialization in response to wounding or UV
damage (17-19) as well as promotes neoplasia and hyperproliferative disease states (3,
20). In the differentiated epidermis, EGFR occupancy by juxtacrine EGFR ligands is an
important maintenance and anti-anoikos signal for the intact epidermis (21). Its
disruption in wounding or disease leads to ligand shedding and the release of EGFR for
ligand binding and internalization (22, 23). Soluble AREG leads to activation of the proproliferative ERK signaling pathway (22, 24) which is inhibited by Dsg1 at the intact
desmosome (25). Without disruption, membrane-associated AREG prevents
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internalization and signals through the anti-apoptotic PI3K at the cell membrane (26, 27)
or the EGFR silencing PKC (21, 28, 29) which colocalizes to the desmosome (30).
Cleavage of membrane–associated pro-EGFR ligands, important in wound
healing, maintains a proliferative capacity in confluent cell populations (31). In the
differentiating epidermis, MMP-dependent EGFR-ligand shedding is critical to the
maintenance of the epidermal barrier. ADAM17 -/- null mice develop barrier defects
after birth and chronic dermatitis as adults and resemble mice with targeted epidermal
knockout of EGFR (29). Similar to the aforementioned knockout phenotype, EGFR
down-regulation within the differentiating epidermis is not complete. In fact, prolonged
exposure to low level ligands is a mechanism for spatial and temporal regulation of
receptor signaling (32).
It was found, when neutralizing these ligands, that TCDD-induced loss of surface
associated EGFR was reversible following removal of AREG or EREG by neutralizing
antibodies of ligand cleavage through the use of a broad spectrum MMP inhibitor
(Figure 3.6). However, neutralization of ligands in any combination in Ca-treated cells
showed EGFR binding loss to be ligand independent (Figure 2.4). Signaling capacity of
cells under these two conditions proved to be different as well: ERK signaling in Catreated cells was ~55% that of basal cells at 72 hours, and neutralization of EGFR ligands
was unable to restore it to basal levels (Figure 2.3). Conversely, TCDD-treated cells,
with 22% fewer surface-associated EGFRs than the basal cells, had elevated ERK
activity that was attenuated by the use of batimastat or neutralization of all three ligands
(TGF-α, EREG, and AREG) (Figure 3.7).
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Figure 1. Comparison of endpoints for Ca- and TCDD-treated cells.Summarizing
findings relating to EGFR down-regulation, EGF-like ligand secretion, basal ERK
activation, and proliferation.

TCDD causes a Ca-like loss of [125I]-binding, it occurs to a lesser extent, ~71% The
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Finally, the impact of Ca and TCDD on cellular proliferation was also distinct.
Ca-treated cells showed a decrease in total cell number (Figure 2.5), TCDD-treated cells
had similar number to control cells (that was reduced in a ligand-manner (Figure 3.8) as
well as showed a higher proliferative capacity as measured by EdU labelling. Still,
neutralization of EGFR ligand secretion in all treatments led to a significant and marked
decrease in proliferative capacity, suggesting that EGFR signaling, even in differentiating
cells is an essential part of this system. The continued presence of the EGFR may allow
Ca-dependent cells to maintain a proliferative population and in TCDD-treated cells,
where EGFR down-regulation is ligand-dependent, explain how TCDD can
simultaneously mimic portions of epidermal differentiation while simultaneously
maintain proliferative-capacity.
Marked differences (Figure 1) in ability of ligands to account for changes in
EGFR down-regulation, signaling, and proliferation observed following Ca- and TCDDtreatment suggest that Ca-induced alterations to EGFR localization and signaling are to a
large degree, ligand-independent and therefore mechanistically distinct to the changes
observed following TCDD exposure and therein may lie the difference in Ca- versus
TCDD-induced keratinocyte differentiation. Cell number, while maintained by EGFR
dependent proliferative capacity which maintained by a small portion of NHEKs is in
both cases ligand-dependent, however, it the complement of ligands which impact how
strongly this effect is.
Taken together, our data lead us to two important conclusions on Ca- and TCDDinduced differentiation.
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1. That EGFR down-regulation observed in both Ca and TCDD-treated cells
does not correlate with a loss of proliferative capacity though its effects on
ERK activation and cell number differ.
2. Down-regulation observed in Ca- versus TCDD-treated cells is
mechanistically different: neutralization of EGFR ligands leads to reversal of
EGFR binding and altered ERK activation in TCDD-treated cells, while
down-regulation in Ca-treated cells is ligand independent

However, the difference may not be so clearly defined as physiological versus
pathophysiological differentiation. The difficulty of exploring the contradictory
proliferative and differentiating role of TCDD in the epidermis through the use of
monolayer keratinocyte culture of keratinocytes pidermally, Ca is not present in the
dichotomous form of “high” or “low” within the epidermis. Instead, Ca represents a
complex gradient with low Ca basally and higher Ca suprabasally (37, 38). Comparison
of high Ca and TCDD compares cells under pro-differentiating and pro-proliferating, low
Ca conditions respectively.
It is difficult therefore, to parse whether the ability of TCDD treated cells is due to
the fact that cells in low Ca better replicate the effects of TCDD on basal cells compared
to high Ca better representing the Suprabasal layers of the epidermis. This work performs
the necessary examinations into the differing role of Ca and TCDD on EGFR downregulation, and and signaling within the epidermis which paves the way for deeper
explorations of the effect of TCDD in differentiating cells.
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APPENDIX A
Supplemental Figures for Chapter Two
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Fig. A1. HB-EGF in NHEK-conditioned medium is below detectable
limits. NHEKs were treated for increasing times with Ca (1.8 mM) and
culture medium was collected. HB-EGF (A) standard curve and (B) medium
concentration were determined by ELISA assay. Standard curve represents
means of one assayed in duplicate. In both control and Ca-treated NHEKconditioned medium, HB-EGF concentration was below detectable levels in
three experiments assayed in triplicate.
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Fig. A2. Reducing EREG availability has no further effect on Cainduced EGFR down-regulation. NHEKs were treated with or without Ca
(1.8 mM) for 72 h in the absence or presence of neutralizing antibodies for
AREG (15 µg/ml), EREG (5 µg/ml), TGF-α (5 µg/ml), or all three growth
factors (anti-all-GF) for 72 h. The measurement of biotin-EGF binding was
then determined as described in the Material and methods section. Basal
refers to medium (K-SFM) without Ca; control refers to treatments in the
absence of neutralizing antibodies. Data are means + SEM of three
experiments assayed in triplicate, normalized to crystal violet staining, and
reported as the % biotin-EGF bound in basal control cells. (a) indicates
significantly different from the basal control at p (< 0.05). * indicates
significantly different from the within treatment control (p <0.05) and
indicates that anti-EREG together or separately do not have a significant
effect on EGFR down-regulation in Ca treated cells beyond that of AREG
and/or TGF-α.
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APPENDIX B
Effects of co-treatment of TCDD in high calcium on EGFR signaling dynamics in
NHEKs

Supplemental Methodology
Cells were grow and treated as described in the body of this Dissertation unless
otherwise mentioned. Briefly, fifth passage NHEKs were grown to confluence, switched
to basal K-SFM for 48 hours then treated with K-SFM with 1.8 mM Ca, 10 nM TCDD,
or both 1.8 mM Ca and 10 nM TCDD. Neutralizing antibodies and inhibitors were used
at the same concentrations described in text and figure legends.
Protocols for [125I]-EGF binding, PACE assays, biotin-EGF binding, and EdU
labelling were performed as addressed in the body of this work.
Determination of cell number
In lieu of double stranded DNA analysis, relative cell number was determined via
crystal violet staining as described by Kueng et al (1989). Briefly, formaldahyde fixed
cells were washed and stained with 0.04% crystal violet (Sigma Aldrich, St. Louis, MO)
(w/v) in 4% ethanol (Kueng, et al., 1989; Kramer, et al., 2008) . Cells were lysed
overnight in 10% SDS and lysates read at 595 nm.
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Figure 1. TCDD/Ca caused sustained [125I]-EGF binding loss. NHEKs were
grown as described in the body of this Dissertation then (A) treated for the times
indicated with EGF (100 ng/ml) or TCDD/Ca (10 nM/1.8 mM) for 4-72 h then
[125I]-EGF binding was determined as described in . Data are expressed as the %
time-matched control (TMC) and reported as the means + SEM of three experiments
assayed in triplicate. (B) TCDD/Ca co-treatment reduces [125I]-EGF binding below
beyond TCDD or Ca alone. NHEKs were treated for 72 h with 1.8 mM Ca, 10 nM
TCDD, or TCDD/Ca then [125I]-EGF binding was determined. Data are expressed
as the % TMC and represent means + SEM of three experiments assayed in
triplicate. The dashed line in (A) and (B) indicates 100%. * indicates significantly
different from time-matched control (TMC) (p<0.05), a indicates significantly
different from TCDD (p<0.05), The dashed line indicates 100%.
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Figure 2. The effect of TCDD, Ca, and TCDD/Ca on TGF-α and AREG
secretion. NHEKs were treated for 4, 24, or 72 h with TCDD/Ca (10 nM/1.8 mM),
and conditioned medium was collected. (A) TGF-α or (B) AREG content were
determined by ELISA as described in the body of the Dissertation. Data are means
+ SEM of three experiments assayed in duplicate. EREG has not been investigated
in these cells.
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Figure 3. The effect of TCDD/Ca on ERK activation. NHEKs were treated for 72
h with TCDD/Ca (10 nM/1.8 mM) in the presence or absence of batimastat (bat; 3
M) or the EGFR inhibitor, PD153035 (300 nM) and basal ERK activity was
measured at 72 h via PACE assay as described in the body of this Dissertation. (A)
TGF-α or (B) AREG content were determined by ELISA as described in the body of
the Dissertation. Data are means + SEM of three experiments assayed in triplicate
normalized to basal control cells, though PD153035 represents duplicate
experiments.. *,** indicates significantly different from the within treatment control
(p<0.05 and p<0.01, respectively). † indicates significantly different from the basal
control (p <0.05). The dashed line indicates the basal control. Role of individual
neutralizing antibodies has not been performed.
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Figure 4. Reducing TGF-α availability modifies EGFR down-regulation.
NHEKs were treated with or TCDD/Ca (10 nM/1.8 mM) for 72 h in the absence or
presence of batimastat (bat; 3 μM) or neutralizing antibodies for TGF-α (5 μg/mL),
AREG (15 μg/mL), or both for 72 h followed by the measurement of biotin-EGF
binding as described in the body of this Dissertation. Basal refers to K-SFM without
TCDD/Ca; control refers to treatments in the absence of batimastat or neutralizing
antibodies. Data are means + SEM of six experiments assayed in triplicate,
normalized to crystal violet staining, and reported as the % biotin-EGF bound in
basal cells. a indicates significantly different from the within treatment control (p
<0.05). The dashed line indicates 100%.
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Figure 5: Inhibiting EGFR activity or reducing TGF-α availability have
distinct effects on DNA synthesis and cell number. NHEKs were grown to
confluence in glass chamber slides and then treated for 72 h with TCDD (10 nM),
Ca (1.8 mM), or TCDD/Ca (10 nM/1.8 mM) in the presence or absence of
PD153035 (300 nM), an EGFR inhibitor. During the last 16 h they were incubated
with 10 mM EdU and labeled as described in the body of this Dissertation. (A)
Representative confocal images of total (DAPI; 405 nm, blue) and EdU-staining
nuclei (647 nm, pink) at 20x magnification. (B) Proliferative index of Edu positive
nuclei per field (EdU labeled/DAPI labeled). Data are means + SEM from
quantifications of five fields from three separate experiments. * indicates
significantly different from the within treatment control (p<0.05 and p< 0.01
respectively). (C) NHEKs were grown to confluence and then treated for 72 h with
TCDD, Ca, or TCDD/Ca in the presence or absence of neutralizing antibodies for
TGF-α (5 μg/mL), AREG (15 μg/mL), or both. After treatment, cells were fixed in
4% formaldehyde and stained with 0.04% crystal violet as described in the
Supplemental Methods. Data are means + SEM of three separate experiments
assayed in triplicate and reported as percentage of time-matched control. a indicates
significantly different from the basal control (p<0.05). The dashed line indicates
100%.
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Table 1. Comparison with TCDD and Ca treatments
Characteristic
EGFR down-regulation
EGFR ligand secretion
EGFR signaling at 72 h

Cell number
Proliferative Index

TCDD
Liganddependent
↑ TGF-α
Reduced
Ligandindependent
Reduced
No Change

Ca

TCDD/Ca
Ligand-independent

Ligand-dependent (?)

↑ TGF-α
↑ EREG

↑ TGF-α
EREG?

Increased
Ligand-dependent

Increased
MMP-dependent

No change
Enhanced

Increased (crystal violet)
Indeterminate
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APPENDIX C
RaybiotechTM sandwich ELISA-based arrays as a screen for NHEK-secreted
ligands, changes in ErbB receptor complement, and ErbB phosphorylation At
common sites

EGFR ligands in NHEK conditioned medium
Design and methology
Before pursuing whether EGFR down-regulation occurred through a liganddependent or independent mechanism, we first needed to know whether or not EGF-like
ligands recognized by the EGFR were available at our experimental timepoints. In order
to assess which if any EGFR ligands were available in NHEK-conditioned medium, we
designed a custom ligand array from RayBiotech (Norcross, GA). Ligands were selected
via TCDD-induced fold change in a keratinocytes microarray (1), literature search, and
ligand availability. Literature was searched alongside Raybiotech antibody availability by
utilizing PubMatrix (2), an NCBI literature mining tool. At the time, available ligands
(n=292) were searched in pubmed against the terms: epidermis, keratinocyte, epidermal
differentiation, skin, psoriasis chloracne, TCDD, epidermal disease, EGFR, calcium, and
EGFR transactivation. Ligands were then ranked on a scale of 0-6 in each search wherein
0 was no results 1 < 10 related articles, 2 < 25 related articles, 3 < 50 related articles, 4 <
100 related articles, 5 < 500 related articles, and 6 < 1000. Within the top 100, we found
TGF-α (ranked 5th), AREG (ranked 44th), HB-EGF (ranked 24th), and BTC (ranked 99th).
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Capture antibodies for custom arrays were pre-dotted on nitrocellulose paper.
Upon receipt, samples were incubated for 30 minutes at room temperature with
proprietary blocking buffer before being incubated with 1 mL of cell culture conditioned
medium for two hours at room temperature. Membranes were then washed five times
with two proprietary washing buffers and incubated for one hour at room temperature
with a mixture of biotin-conjugated anti-cytokine antibodies, washed again, and
incubated for two hours with HRP-conjugated streptavidin. Membranes were then
washed and developed via enhanced chemiluminescence on x-ray film. Film was scanned
and spots quantitated using ImageJ software. Values are reported as arbitrary units (AU)
that have been background subtracted and normalized to positive controls. Each
membrane contained duplicate spots for each ligand and due to cost and the fact that this
experiment served as a screening tool, each treatment x timepoint was performed on one
membrane.
Identification of NHEK-secreted ligands
We found that TGF-α, HB-EGF, and AREG were secreted in cells under our
treatment conditions (Figure 1). BTC had significant background even on the negative
control membrane (incubated with basal K-SFM), suggesting it reacted to a component of
the media. Regardless, no BTC effect was found. TGF-α increased 1.58-fold over basal in
Ca treated cells, 2.49-fold in TCDD-treated cells, and 2.95-fold in TCDD/Ca-treated cells
comparable to the 2.83-fold and 3.22-fold observed in Ca and TCDD-treated cells via
ELISA (Figure 1). However, HB-EGF increased 1.97-fold, 2.58-fold, and 2.86-fold in
Ca, TCDD, and TCDD/Ca-treated cells however was not detected in a ELISA for human
HB-EGF with a lower detection limit of 6.55 pg/mL. AREG increased 1.18, 1.81, and
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1.97-fold in Ca, TCDD, and TCDD-treated cells. EREG was not examined as it was not
available at the time of this screen, however an ELISA assay became available after this
initial screening and EREG was also analyzed. ERK activation or binding loss in TCDDtreated cells.

Figure 1. EGFR ligands increased in NHEK-conditioned medium. NHEKs were
grown as described in Methodology TGF-α, HB-EGF, and AREG were assayed on a
custom sandwich ELISA-based array. Antibody arrays were developed via (A)
autoradiography and (B) quantitated via ImageJ. Data are representative of one
experiment assayed in duplicate and background subtracted. Betacellulin (BTC) was
also assayed but due to high non-specific binding on the control blot, we were unable to
get any positive signal. ** indicates significantly different from basal cells (p<0.01).

Changes in phosphorylation of common sites on EGFR, ErbB2, and ErbB3 in
NHEKs
Design and methology
To investigate how EGFR phosphorylation was altered, we first examined
common EGFR phosphorylation sites (Table 1). Using another custom array from
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Table 1. Fold change in phosphorylation of tyrosine, serine, and threonine residues
on ErbB receptors at 72 hours
EGFR
Phosphosite

Function

Y845

Phosphorylated by Src.
Activates Ras and Stat5
Phosphorylated by EGFR/ErbB2.
Activates STAT3, PKC, Erk, Vav2
Phosphorylated by EGFR/ErbB2.
Recruits c-Cbl for ubiquitinylation
Phosphorylated by EGFR/ErbB2
Ras, STAT3, c-Jun, AP-1
Phosphorylated by ErbB receptors,
Activates Ras, STAT3, c-Jun, and
AP-1
Unknown phosphorylation
mechanism. Activates MAPK,
STAT1, and AP-1
Autophosphorylated.
Activates MAPK, PLCγ, Shp2
Phosphorylated by Cam Kinase II.
Causes c-Cbl-independent
internalization/ubiquitinylation
Phosphorylated by Cam Kinase II.
Causes c-Cbl-independent
internalization/ubiquitinylation
Function

Y992
Y1045
Y1068
Y1086

Y1148

Y1173
S1046

S1070

ErbB2
phospho-site
Y887
Y1112
Y1221
Y1248

T686
S1113
ErbB3
Phosphosite
Y1299

Phosphorylated by Src
Activates STAT3 and PKA
Phosphorylated by EGFR/ErbB2.
Recruits c-Cbl for ubiquitinylation
Shc, ErbB2
Phosphorylated by unknown
mechanism.
Activates Shc and ErbB2
Phosphorylated by PKC.
Leads to internalization
Phosphorylated by Cam Kinase II.
Unknown function
Function

Basal
(AU)

EGF
(FC
over
basal)

Ca
(FC
over
basal)

TCDD
(FC
over
basal)

48.92

ND

+2.15

-1.39

+3.63

31.11

ND

+1.46

-1.52

+9.64

31.67

-ND

+1.79

-2.71

+9.66

14.86

ND

ND

ND

ND

ND

ND

ND

ND

ND

30.27

ND

ND

ND

- 9.01

25.92

ND

ND

ND

+3.09

22.02

ND

ND

ND

+5.62

ND

ND

ND

ND

ND

Basal

EGF

2.46

ND

ND

ND

ND

ND

ND

ND

ND

ND

3.53

ND

ND

ND

ND

11.46

ND

+6.95

+3.61

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

Basal

EGF

ND

ND

Phosphorylated by an unknown
mechanism.
Activates PI3K
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Ca

Ca

ND

TCDD

TCDD

ND

TCDD/Ca
(FC over
basal)

TCDD/Ca

TCDD/Ca

ND

Raybiotech, we assayed changes in the phosphorylation of thymine, serine and threonine
residues.
Capture antibodies were pre-dotted on nitrocellulose paper for phosphosites on
ErbB1, ErbB2, and ErbB3. Upon receipt, NHEKs grown for 72 hours in the presence of
EGF (100 ng/mL), Ca (1.8 mM), TCDD (10 nM), or TCDD with 1.8 mM Ca (TCDD/Ca)
were lysed in proprietary lysis buffer and quantitated using a Micro-BCA assay (Pierce
Biotechnology, Rockford, IL) and equal amounts of protein were incubated for 2 hours at
room temperature on membranes that had been pre-blocked for 30 minutes at room
temperature with proprietary blocking buffer. Membranes were then washed five times
with two proprietary washing buffers and incubated for one hour at room temperature
with a mixture of biotin-conjugated anti-cytokine antibodies, washed again, and
incubated for two hours with HRP-conjugated streptavidin. Membranes were then
washed and developed via enhanced chemiluminescence on x-ray film.
Film was scanned and spots quantitated using ImageJ software. Values are
reported as arbitrary units (AU) that have been background subtracted and normalized to
positive control. Each membrane contained duplicate spots for each ligand and due to
cost and the fact that this experiment served as a screening tool, each treatment x
timepoint was performed one membrane.
Identification of ErbB phosphorylation sites
We found that most altered sites following Ca, TCDD, or TCDD/Ca were on
ErbB1 (Figure 2).
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Figure 2. Phosphorylation sites on the EGFR at 72 hours. Keratinocytes
were treated for 72 hours with EGF (100 ng/mL), Ca (1.8 mM), TCDD (10
nM), or TCDD/Ca. Not shown, Y1068, which had no detectable result. Data
represent one experiment with duplicate spots. Data are background
subtracted AU normalized to total EGFR protein and positive control.
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